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CHAPTER I  
INTRODUCTION 
INTRODUCTION 
The central nervous system (CNS) is essential for the survival of 
mammalian life.  Two physiological functions of the CNS vital to that existence 
are sleep and pain sensation.  Both encompass complex biological systems 
involving both the central and peripheral nervous systems to coordinate behavior 
with the external environment.  Although the functions of sleep are not fully 
elucidated, sleep has a regulatory role in many homeostatic functions(1).  Pain 
sensation is critical to protect organisms from external harm and ensure ongoing 
health. However, pain becomes pathological when acute pain sensation 
transitions to a chronic pain state.  Characteristics of chronic pain include 
physical and/or emotional discomfort associated with tissue damage, and often 
persists after tissue heals(2). Sleep disorders in America impact an estimated 70 
million patients and over 30% of the population reports insufficient sleep(3).  
Chronic pain also effects approximately 100 million Americans(4). The combined 
treatment costs of insufficient sleep and chronic pain are estimated in the trillions 
of dollars annually for the United States and represent substantial public health 
problems(3, 5).  Sleep and pain have a bi-directional relationship; pain disrupts 
sleep quality and poor sleep enhances pain(6, 7).  The immune system serves a 
regulatory role in physiological sleep and contributes to chronic pain, making it a 
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potential mechanism of interaction between sleep and pain(8, 9).  The body of 
this dissertation investigates the relationship between sleep and chronic pain in a 
pre-clinical model of musculoskeletal pain with a focus on the role of cytokines. 
SLEEP 
Sleep, despite its ubiquitous nature, is one of the great unknowns in 
biology.  Sleep is an essential function to maintain health, however 40% of the 
US population experiences at least one symptom of insomnia per year(10).  
Sleep is characterized as a behavioral state of decreased responsiveness that is 
rapidly reversible and quantified by the recording the electroencephalogram 
(EEG) and scoring for sleep state. Arousal states are broadly categorized into 
three stages; wakefulness, non-rapid-eye-movement (NREM) sleep, and rapid-
eye-movement (REM) sleep.  Sleep regulates homeostatic biological functions 
including pain and immune function. Conversely, challenges to the immune 
system and chronic pain impact the quality and quantity of sleep duration.  For 
these reasons, the interrelationship among sleep, pain and the immune system 
are of interest.  
The physiological mechanisms linking sleep and the immune system have 
been greatly elucidated during the last 40 years(9).  Cytokines, small signaling 
molecules of the immune system, serve a functional role in sleep regulation 
under normal physiological and pathological conditions, including infection(11).  
Interleukin-1β (IL-1), IL-6, and tumor necrosis factor-α (TNF) are three cytokines 
that regulate the inflammatory response (discussed below).  IL-1 and TNF are 
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sleep regulatory substances and IL-6 also modulates sleep(11, 12). Briefly, the 
roles of IL-1, IL-6 and TNF with respect to sleep are described. 
IL-1 and TNF are cytokines that promote NREM sleep and induce 
symptoms associated with sleep loss(13).  Administration of either IL-1 or 
TNF(14, 15), which mimics the normal accumulation of IL-1 and TNF across 
periods of wakefulness, induce cognitive impairment(16) and sleepiness(17); 
both symptoms of sleep loss.  Sleep loss symptoms are diminished or blocked 
through the administration of cytokine inhibitors(18, 19).  Protein and mRNA 
concentrations of IL-1 and TNF exhibit a diurnal variation in brain regions that 
correlates with sleep propensity(20, 21).  After sleep deprivation, increases in 
NREM sleep, IL-1, and TNF expression occur in brain(22). Central injection of IL-
1 or TNF, in addition to increasing the amount of time spent in NREM sleep, 
enhances the EEG delta (0.5 – 4 Hz) power (a measure of sleep intensity(23, 
24)) during NREM sleep but not during wakefulness or REM sleep(15).  
Enhancement of delta power during NREM sleep is a characteristic of recovery 
sleep after prolonged wakefulness(25, 26).  Collectively, these data support that 
IL-1 and TNF regulate sleep-wake behavior, especially NREM sleep. 
IL-6 exerts effects on sleep. In humans IL-6 secretion is under circadian 
control, with serum concentrations being lower during the daytime and higher at 
night(27), and delaying sleep onset postpones IL-6 secretion(28).  Administration 
of exogenous IL-6 increases NREM sleep in rats(29).  Genetic loss of IL-6 using 
a ligand knockout mouse does not change baseline sleep behavior, but does 
alter the responses of mice to sleep deprivation(30).  In healthy human subjects, 
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IL-6 administration increases NREM sleep and fatigue(31).  Inhibition of IL-6 is a 
common treatment for rheumatoid arthritis and significantly reduces patient 
reported fatigue and improves subjective sleep quality(32, 33).  These data 
support the modulatory role of IL-6 in sleep-wake behavior. 
Disordered sleep is an escalating problem as sleep duration and quality 
decline(3).  Causes of disordered sleep include social distractions (broadly 
termed as ‘social jetlag’(34)) and increases in light availability(35). Experimental 
sleep restriction and deprivation in humans cause insulin resistance and increase 
caloric consumption, diminish immune response, impair decision-making, reduce 
attention span, reduce cognitive speed, and decrease tolerance to painful 
stimuli(36-45).  Epidemiological evidence demonstrates that in humans habitually 
short sleep duration increase the incidence rates of obesity, diabetes, glucose 
intolerance, cardiovascular disease, susceptibility to infection, and chronic 
pain(46-55).  Short sleep duration is also linked to an increase in risk of all-cause 
mortality(56). Although the biological mechanisms underlying increases in 
disease risk are the subject of ongoing research, short sleep duration is a 
contributing factor to disease states including chronic pain and immune function. 
The functions of sleep are studied through the experimental deprivation of 
sleep in humans and rodents.  Methods of total sleep deprivation eliminate both 
NREM and REM sleep(57).  REM sleep deprivation selectively targets REM 
sleep for elimination while leaving NREM sleep intact(58).  These techniques 
yield data from humans and rodents, however sleep deprivation does not model 
the human condition of disrupted sleep.  Sleep disruption has many causes 
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including sleep disorders, chronic medical conditions, shift work, and pain(7, 59, 
60).  Characteristics of sleep disruption include brief arousals during sleep that 
do not reduce total sleep time(61), but increase daytime sleepiness and impair 
cognitive function(62).  Sleep disruption of humans and rodents increases 
concentrations of circulating cytokines including IL-1, IL-6, and TNF(63, 64).  
Interest in modeling the human condition of disrupted sleep led to the 
development of sleep fragmentation (SF) techniques(65, 66) that fragment sleep 
without reducing overall sleep time. One method validated by our laboratory 
fragments the sleep of mice for prolonged periods of time using a rotating 
disc(65).  The use of this device during the light period to disrupt sleep is thought 
to more closely model the human condition of sleep disruption(65).  For these 
reasons this dissertation will utilize SF to investigate the impact of sleep 
disruption on subsequent pain and sleep behavior. 
CYTOKINES  
The immune system is broadly divided into the innate immune system, 
which encompasses numerous antimicrobial mechanisms(67), and the acquired 
immune system that uses antibodies and cytotoxic cellular mechanisms(68).  
One of the primary functions of the innate immune system is to recruit immune 
cells to the site of the infection to segregate biological threats for removal(68).  
The innate immune system isolates and destroys invading pathogens through 
antigen recognition and inflammatory processes(67). The innate immune system 
response activates major effector cells, which include neutrophils, monocytes, 
natural killer cells, natural killer T lymphocytes, and γδ T cells, all of which 
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release cytokines(69).  Cytokines are specialized mediators of the immune 
system that signal during normal physiological and pathological conditions.   
Cytokines are small (8-30 kilodaltons) molecules used by the immune 
system for endocrine and paracrine signaling (70).  The term cytokine applies to 
over 100 proteins, peptides, and glycoproteins that signal and recruit immune 
cells to the site of an infection.  Cytokines are broadly divided into two major 
categories: pro-inflammatory and anti-inflammatory.  Pro-inflammatory cytokines 
include IL-1, IL-6, and TNF; three of the most extensively studied cytokines.  IL-1, 
IL-6, and TNF are produced from virtually all nucleated cells, especially resident 
macrophages, endothelia, and epithelial cells.  IL-1, IL-6, and TNF trigger 
inflammatory cascades that contribute to a number of physiological and 
pathological processes, including sleep and pain(13, 71). The function of each of 
these cytokines in the immune system is briefly discussed below. 
IL-1 is an inflammatory cytokine with a size of ~ 36 kDa that is created 
when pro-IL-1 is cleaved into active form by caspase-1(72, 73). IL-1 is produced 
in response to an injury, infection or immune challenge(74).  IL-1 causes fever 
and contributes to the production of other proinflammatory cytokines(74, 75).  
Two receptor subtypes bind IL-1; IL-1 receptor 1 (IL1-R1) and IL-1 receptor 2 
(IL1-R2).  IL1-R1 interacts with a cytoplasmic accessory protein to form a 
complex that recruits adaptor molecules(76).  This signaling activates the 
transcription factor NF-κB that in turn triggers complex intracellular cascades(69). 
IL1-R2 lacks an intracellular domain and as such acts as a decoy receptor(77, 
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78).  Foreign organisms and their byproducts stimulate IL-1 production(79),  as 
well as cytokines including TNF(80), and IL-1 itself(80, 81).   
TNF activates inflammatory response cascades and was first identified as 
a product of macrophages and lymphocytes that lyses cells, especially tumor 
cells, conferring its name(82).  TNF is synthesized as a membrane-bound 
homotrimer, pro-TNF, that is cleaved by the TNF converting enzyme and creates 
the soluble cytokine that interacts with cell-surface receptors(83, 84).  TNF, like 
IL-1, has two receptors, TNF receptor 1 (TNF-R1) and TNF receptor 2 (TNF-R2), 
which are structurally related but differ with respect to their affinity for ligands and 
cellular expression(84).  Both of the TNF receptors signal through transcription 
factors, including NF-κB(85).  The activation of these transcription pathways is 
critical in the immune response, release of cytokines, and induction of cell 
apoptosis and necrosis(86). 
Interleukin-6 (IL-6) is a protein critical in the maturation of B cells into 
antibody-producing cells(87).  IL-6, in addition to differentiating B-cells, 
contributes to the regulation of other immune cells, hepatocytes, and the skeletal, 
cardiovascular, endocrine, and nervous systems(88).  Neurons, astrocytes, 
microglia, and endothelial cells produce IL-6, especially after injury(89).  IL-6 
binds to class I cytokine receptors that include gp130 which is ubiquitously 
expressed(88).  The specific receptors for IL-6 comprise a soluble (sIL6R) and 
membrane bound (mIL6R) receptor whose expression are restricted to specific 
tissues(90).  Upon recruitment of gp130 after binding of IL-6, intracellular 
signaling is activated(91).  Changes in the gene transcription of NF-κB regulate 
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IL-6 secretion, although post-transcriptional mechanisms also regulate IL-6 
secretion(92, 93).  IL-6 is an inflammatory cytokine although it also exhibits 
indirect anti-inflammatory effects by inhibiting TNF and IL-1 via release of IL-1 
receptor antagonist and IL-10, an anti-inflammatory cytokine(94, 95).  IL-6 is also 
considered to be a myokine, or a cytokine directly released from muscle tissue, 
especially after muscle contraction(96, 97).   
Cytokines serve a functional role not only in immune responses, but also 
sleep and pain.  The role of cytokines in the regulation of sleep, especially NREM 
sleep, is already touched upon.  Briefly, the roles of cytokines in acute and 
chronic pain are discussed below. 
PAIN 
Chronic pain is the most prevalent disease in the United States with 100 
million American’s reporting chronic pain during their lifetime(4).  Unfortunately, 
over 75% of persons with chronic pain will have insufficient control over their 
pain(4).  These numbers contribute to the $675 billion in annual costs associated 
with medical treatment and lost work productivity related to chronic pain(5).  
Three of the most prevalent types of chronic pain in the United States are 
musculoskeletal in nature and include low back pain, neck pain, and facial 
pain(4).  The pervasiveness of chronic musculoskeletal pain supports the need 
for research, especially pre-clinical research, to elucidate the biological 
mechanisms underlying muscle pain and develop effective treatments(4).   
There are many causes of chronic pain. A direct injury or insult to the 
central nervous system causes neuropathic pain and often results from surgery 
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or traumatic injury that can crush, tear, or sever the nervous system.  Tissue 
inflammation activates the immune system and causes inflammatory pain.  
Damage to the joints and connective tissues causes rheumatic pain and is often 
progressive in nature, such as during osteoarthritis.  Musculoskeletal pain is 
associated with conditions including fibromyalgia and a number of painful 
myopathies.  Musculoskeletal pain is important not only because of its frequency, 
but also the escalating costs of treatment(98, 99).  The most prevalent workplace 
injuries involve musculoskeletal pain, and pain control is the biggest barrier in 
returning to work(100).  Furthermore, control of musculoskeletal pain is often 
poor and may require the ongoing use of opioids that poses risks of dose 
escalation to achieve pain control and drug dependence(101).  Patients with 
musculoskeletal pain also have a poorer quality of life compared to patients with 
chronic gastrointestinal conditions, renal disease, and cardiovascular 
conditions(102).  The study of musculoskeletal pain is necessary to reduce 
economic costs, identify treatments, and improve patient quality of life. 
Nociception is the process of detecting a physical threat in the form of 
mechanical, chemical, or thermal stimuli that are of a sufficient intensity to 
produce tissue damage(103, 104). Sensing noxious stimuli is different from non-
noxious physical sensation of the external environment and uses unmyelinated c 
fibers and thinly myelinated Aδ fibers, generally termed nociceptors(2).  
Nociceptors detect noxious sensations including harmful cold, heat, pressure, 
chemicals, and hydrogen ions (H+) and synapse from the periphery into the 
dorsal horn of the spinal cord(2).  The dorsal horn integrates, processes, and 
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outputs sensory information from the spinal networks that project to the brain in 
several discrete pathways that detect the discriminative and emotional aspects of 
pain(105).  These ascending pathways further relay information on to the cortex.  
The ascending pain pathways, from the periphery to CNS, mediate the basic 
sensation of acute noxious stimuli. 
Descending pathways from the brain to the spinal cord facilitate and inhibit 
pain sensation(106).  Inhibitory mechanisms have evolutionary importance 
because they enable an organism to suppress pain in situations that may require 
‘fight or flight’ to survive(107).  Descending pain pathways include the 
hypothalamus, amygdala, and cortex that send projections to the midbrain 
periaqueductal gray (PAG) region.  The PAG outputs synapse in the medulla 
within the rostral ventromedial medulla (RVM) and project to the dorsal horns of 
the spinal cord(108).  A large body of research from pharmacological, 
electrophysiological and anatomical studies identifies the periadueductal gray 
(PAG) and rostroventral medulla (RVM) as being critical nuclei in regulating 
sensory processing in the dorsal horn(108-110).  Chronic pain can impair 
descending inhibition of pain.  
Central sensitization is a term that broadly describes the augmentation in 
nociceptive pathway functions during chronic pain(111).  The neural plasticity 
associated with central sensitization occur at diverse anatomical (molecular, 
cellular, synaptic, and network) and temporal (acute to chronic) scales(112).  
Central sensitization leads to pre- and post-synaptic potentiation through 
regulation of neurotransmitter release and receptor expression(111).  
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Characteristics of central sensitization include increases in neuronal excitability, 
both spontaneous and evoked, the expansion of nociceptor receptive fields, and 
the reduction of threshold for nociceptor action potentials(113).  Structurally, 
synaptic spine density can increase or decrease during chronic pain.  
Denervation and hypertrophy can enhance pain, despite having converse effects 
on cellular connections(111).  Modulation of cell numbers in brain gray matter, 
cell death and cell proliferation in the spinal cord all are associated with chronic 
pain states(113).  Trends in regulation of structures involving nociceptive 
transmission are emerging, although the specific changes during chronic pain 
differ across research models. 
Musculoskeletal sensitization models muscle pain in pre-clinical rodent 
models.  Musculoskeletal sensitization uses two injections of acidified saline (pH 
4.0) unilaterally into the gastrocnemius muscle spaced 5 days apart to produce 
long lasting bilateral secondary mechanical hypersensitivity at the hindpaws(114-
116).  Mechanical hypersensitivity is measured by quantifying hindpaw 
withdrawals to calibrated pressure von Frey monofilaments(117).  The 
musculoskeletal sensitization model does not cause classical signs of pain 
including weight bearing preference, impaired locomotor function, guarding of the 
limb, or limping(114).  The bilateral mechanical hypersensitivity at the hindpaws 
during musculoskeletal sensitization is the result of changes in the CNS, not the 
periphery(118, 119). This makes musculoskeletal sensitization an ideal model to 
study interactions with sleep, a process mediated entirely by the CNS.  
Peripheral tissue damage or impairment of locomotor function, as seen during 
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pre-clinical models of osteoarthritis and neuropathic pain, make interpreting the 
relationship between sleep and pain challenging as changes in sleep could result 
from limited mobility. The lack of peripheral tissue damage allows for a targeted 
interaction of sleep with musculoskeletal sensitization. Musculoskeletal 
sensitization in mice is utilized in this dissertation to investigate mechanistic 
interactions between musculoskeletal pain and sleep. 
PAIN AND CYTOKINES 
The activation of the inflammatory process is classically associated with 
pain (dolor), redness (rubor), swelling (tumour), heat (calor), and loss of function 
(function laesa).  Cytokines are part of the inflammatory immune response and 
contribute to proper wound healing at the site of injury and infection(120). 
However, excessive or prolonged inflammation can interfere with normal 
homeostatic function and contribute to pathological pain states(8).  IL-1, IL-6, and 
TNF all serve functional roles in the inflammatory response following injury, 
infection, and modulate pain(121).  Briefly, the role of each individual cytokine 
with respect to pain is reviewed. 
IL-1 is primarily produced by macrophages, monocytes, and non-immune 
cells including activated fibroblasts during cellular damage, inflammation and 
infection(75).  IL-1 produces systemic inflammation through activation of the 
cyclooxygenase-2 pathway that is commonly targeted for pain reduction through 
the use of non-steroidal anti-inflammatory (NSAID) drugs(71).  IL-1 also activates 
the production of substance P (SP), nitric oxide, and endothelial adhesion 
molecules, all of which contribute to the development and maintenance of 
13 
 
pain(71, 122).  Dorsal root ganglion cells of the spinal cord express IL-1 
receptors in nociceptive neurons(71, 123), providing a direct mechanism for pain 
enhancement(124).  Central or peripheral injection of IL-1 produces lasting pain 
in rodents(125).  Furthermore, antagonism of IL-1 prevents the development of 
pain in an experimental model of neuropathic pain(126, 127). Collectively, these 
data support the role of IL-1 in pain. 
TNF is one of the first cytokines identified, along with IL-1, to cause 
pain(128).  In a variety of clinical conditions, including fibromyalgia and 
rheumatoid arthritis, TNF is elevated in patients(129).  Increases in cytokine 
concentrations correlate with augmented pain for patients with chronic pain 
conditions(130).  Administration of TNF using injection or topical application 
produces pain in pre-clinical models(131-135).  The painful effects of TNF are 
reversible through the co-administration or pre-treatment with TNF receptor 
antagonists in models of neuropathic pain and diabetic pain(136-138).  Clinically, 
these findings are reproduced using pharmaceutical TNF receptor antagonists 
and inhibitors for the treatment of pain caused by rheumatoid arthritis(139, 140). 
Collectively, these data support a role of TNF in the regulation of pain. 
IL-6 is a cytokine critical to the acute phase response of the innate 
immune system(89, 94).  IL-6 is released during trauma, infection, injury, surgery, 
burns, and strenuous exercise(89). IL-6 is considered to be one of the most 
relevant markers of tissue damage(141), however it’s role in pain is not as well 
elucidated as IL-1 and TNF.  IL-6 is an excellent candidate molecule for relaying 
information between the periphery and central nervous system(142).  Gp130, a 
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critical component of IL-6 signaling, is implicated in numerous disease states(88).  
Gp130 amplifies pain through the induction of cytokine release, and genetic 
knockout of gp130 in mice significantly reduces pain to noxious stimuli(143).  
Importantly, IL-6 is an activator of gp130 and downstream signaling cascades 
contributing to the development of pathological pain(143).  Blockade of the IL-
6/IL-6R/gp130 formation is a therapeutic treatment for patients with rheumatoid 
arthritis, multiple myeloma, and Castleman’s disease(144, 145). Antagonists for 
IL-6/gp130 are approved by the FDA for treatment of patients not helped through 
anti-TNF therapy(146-148).  These data demonstrate the importance of IL-6 as a 
pathway for the modulation of chronic pain. 
Cytokines are critical in the acute and chronic pain response.  Although 
the role of cytokines under specific chronic pain states is still being elucidated, 
cytokines contribute to pain processing.  The administration of cytokines to 
produce pain, the blockade of cytokines to relieve pain, and the quantification of 
cytokine protein and gene expression increases following trauma, inflammation, 
and injury demonstrate the role of cytokines during pain. 
SLEEP AND PAIN  
Sleep and pain have bi-directional interactions, with pain disrupting sleep and 
poor sleep enhancing pain(6, 149).  Experimental and observational work in 
clinical and pre-clinical models supports this relationship.  Despite this body of 
work, pre-clinical models have not investigated interactions between sleep and 
musculoskeletal pain.  The need for research between sleep and 
musculoskeletal pain is underscored by the epidemiological data demonstrating 
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large numbers of persons suffering from musculoskeletal pain, insufficient sleep, 
or a combination of these chronic conditions(3, 4, 7).   
Clinically acute and chronic pain interfere with sleep(7). Early studies 
systematically investigating the role of pain on sleep quantified the sleep of 
patients with chronic musculoskeletal, rheumatic, and non-specific pain(150-
152).  All of these patients had diminished sleep quality characterized by sleep 
fragmentation, reduced NREM sleep, reduced REM sleep, and reduced overall 
sleep time(150-152).  Epidemiological data reveal that sleep disturbances, 
especially insomnia, are the highest associated comorbidity with chronic pain, 
with rates ranging between 50 and 98%(60, 153, 154).  Sadly, the negative 
influence of chronic pain on sleep quality holds true for children and adolescents 
with chronic pain(155, 156).  Although this research is only briefly touched upon, 
there is a substantial body of literature demonstrating the negative role of chronic 
pain on sleep quality consistent with data presented(157).   
The influence of pain on sleep is pre-clinically studied through the use of 
animal models of pain(158, 159).  Pre-clinical models investigate osteoarthritis, 
nerve injury, inflammatory pain, and immune related pain(158). A number of pre-
clinical chronic pain models are associated with decrements in sleep quality(160-
167).  Changes in sleep are characterized by a reduction in total sleep time, 
NREM and REM sleep time individually, fragmentation of the sleep period, 
increases in latency to sleep, and changes in EEG characteristics(160-167). Pre-
clinically, rodent models of chronic pain and sleep support the clinical evidence 
that pain disrupts sleep. One gap in the current literature is the influence of 
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musculoskeletal pain on sleep.  Although pre-clinical models of musculoskeletal 
pain are available, none have been investigated with respect to sleep(114, 134).  
This presents an opportunity for pre-clinical research into the influence of 
musculoskeletal pain on sleep. 
Sleep and pain research also investigates the role of sleep in modulating pain 
sensation(168).  Acute and chronic pain is the highest associated co-morbidity 
with primary insomnia(169, 170).  Numerous clinical studies demonstrate that 
experimental sleep deprivation, restriction, or disruption of human subjects 
enhances pain across sensory modalities(45, 171-173).  In the general 
population, persons with a sleep durations outside the 6-9 hour range per night 
have increases in subjective pain(174).  Restorative sleep is a predicting factor in 
the resolution of pain in patients with chronic widespread pain(175). 
Epidemiological data identifies poor subjective sleep quality as an independent 
risk factor in the development of fibromyalgia(55). This body of literature provides 
evidence that sleep quality and duration have a modulatory effect on pain 
perception. 
Pre-clinical sleep disruption, restriction and deprivation of animals enhances 
pain independently, or in conjunction with chronic pain(176, 177).  Sleep 
deprivation is performed through a number of methods either selectively targeting 
REM sleep or total sleep deprivation(66, 178, 179). REM sleep deprivation 
sensitizes rats to thermal stimuli and recovery sleep improves sensitivity(180, 
181).  Numerous studies demonstrate that REM sleep deprivation enhances pain 
across a range of modalities(182-185).  Interest in modeling the human condition 
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has led to the development of animal models of sleep fragmentation(65, 66).  
These models are not as extensively studied for their role in pain as REM sleep 
deprivation because of their recent development.  However, given the body of 
clinical literature linking poor sleep quality with enhanced pain in humans, pre-
clinical studies should yield congruent results.  
Sleep and pain have a bi-directional relationship.  Acute and chronic pain 
disrupt and diminish the quality of sleep in humans and pre-clinical research 
models. The study of clinical patients with chronic pain or the pre-clinical 
induction of chronic pain using rodent models negatively impacts sleep.  
Conversely, poor sleep quality contributes to the enhancement and exacerbation 
of pain.  Deprivation and disruption of the sleep of human subjects or rodents 
enhances pain in healthy subjects and those with pain.  Furthermore, population 
based studies reveal that poor sleep quality is a risk factor for the development of 
chronic pain. Collectively these data support the influence of sleep and pain on 
each other and identify pre-clinical research of musculoskeletal pain as an area 
of research. 
SPECIFIC AIMS 
The central hypotheses of this dissertation are that 1) musculoskeletal 
sensitization will disrupt sleep, 2) cytokines will play a role in mechanical 
hypersensitivity following musculoskeletal sensitization, and 3) sleep 
fragmentation combined with musculoskeletal sensitization will alter the 
behavioral outcomes of musculoskeletal sensitization.  Chapter II quantifies 
sleep/wake behavior of mice after musculoskeletal sensitization using EEG 
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instrumentation for determination of sleep physiology.  Chapter III investigates 
the role of intramuscular cytokines in musculoskeletal sensitization.  These 
experiments quantify inflammatory cytokines in muscle tissue after 
musculoskeletal sensitization, and use pharmacological and genetic tools to 
determine the roles of NF-κB, IL-1, IL-6, and TNF in mechanical hypersensitivity.  
Chapter IV investigates the role sleep fragmentation combined with 
musculoskeletal sensation has in altering behavioral outcomes including 
mechanical hypersensitivity and subsequent sleep.  These hypotheses are 
derived from the literature that pain disrupts sleep, poor sleep enhances pain, 
and cytokines modulate pain.    Elucidating these mechanisms will contribute to 





MUSCULOSKELETAL SENSITZATION AND SLEEP: CHRONIC 
MUSCLE PAIN FRAGMENTS SLEEP OF MICE WITHOUT 
ALTERING ITS DURATION1 
 
ABSTRACT 
Study Objectives: Musculoskeletal pain in humans is often associated 
with poor sleep quality. We used a model in which mechanical hypersensitivity 
was induced by injection of acidified saline into muscle to study the impact of 
musculoskeletal sensitization on sleep of mice.  
Design: A one month pre-clinical study was designed to determine the 
impact of musculoskeletal sensitization on sleep of C57BL/6J mice. 
Methods: We instrumented mice with telemeters to record the 
electroencephalogram (EEG) and body temperature. We used an established 
model of musculoskeletal sensitization in which mechanical hypersensitivity was 
induced using two unilateral injections of acidified saline (pH 4.0). The injections 
were given into the gastrocnemius muscle and spaced five days apart. EEG and 
body temperature recordings started prior to injections (baseline) and continued 
for three weeks after musculoskeletal sensitization was induced by the second 
injection. Mechanical hypersensitivity was assessed using von Frey filaments at 
                                            
1
 The work presented in this chapter are accepted for publication: Sutton, B.C. & Opp, 
M.R. (2013) Musculoskeletal sensitization and sleep: Chronic muscle pain fragments sleep of 
mice without altering its duration. SLEEP, in press. 
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baseline (before any injections) and on days 1, 3, 7, 14, and 21 after the second 
injection. 
Results: Mice injected with acidified saline developed bilateral mechanical 
hypersensitivity at the hind paws as measured by von Frey testing and as 
compared to control mice and baseline data. Sleep during the light period was 
fragmented in experimental mice injected with acidified saline, and EEG spectra 
altered. Musculoskeletal sensitization did not alter the duration of time spent in 
wakefulness, non-rapid eye movement sleep, or rapid eye movement sleep.   
Conclusions: Musculoskeletal sensitization in this model results in a 
distinct sleep phenotype in which sleep is fragmented during the light period, but 
the overall duration of sleep is not changed. This study suggests the 
consequences of musculoskeletal pain include sleep disruption, an observation 
that has been made in the clinical literature but has yet to be studied using 
preclinical models. 
INTRODUCTION 
It is estimated that 1.5 billion people worldwide suffer from moderate to 
severe chronic pain(186). Individuals suffering chronic pain comprise one of the 
costliest patient populations, especially in terms of lost work and reduced 
productivity(187, 188). Persons with chronic pain also report some of the lowest 
quality of life among patients suffering from chronic diseases(102). Poor sleep is 
another major public health issue, with almost 40% of the US population 
reporting chronic insufficient sleep, and 50-70 million Americans diagnosed with 
sleep disorders(3). Sleep disorders and chronic pain are often comorbid 
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conditions, and the overall prevalence and economic burden of chronic pain and 
insufficient sleep make these diseases an important topic of public health 
research. 
Data derived from clinical research supports a bidirectional relationship 
between sleep and chronic pain(149, 176, 189). A variety of chronic pain 
conditions have comorbid sleep disturbances(60, 153, 169). Sleep of patients 
with chronic pain is characterized by difficulty initiating sleep, maintaining sleep, 
excessive nighttime awakenings, and feeling unrefreshed after sleeping(7, 60, 
149, 176). For example, individuals suffering with chronic low back pain have 
insomnia rates over 50%, and subjective pain correlates with severity of 
insomnia(190). Persons with primary insomnia also report chronic pain at rates 
over 50%, the highest associated comorbidity for insomnia(191). Recent 
epidemiological research identifies a history of poor sleep quality as a significant 
risk factor in the development of fibromyalgia(55). Furthermore, experimental 
disruption or deprivation of sleep reduces pain thresholds(172, 176, 192). 
Conversely, extension of the sleep period is sufficient to reduce pain sensitivity, 
suggesting that sufficient sleep may reduce pain(193). Collectively, these and 
other data contribute to our understanding of the relationship between poor sleep 
quality and chronic pain. 
Three of the most prevalent types of chronic pain in our society are low 
back pain, neck pain, and facial pain(4), all of which are musculoskeletal. The 
most prevalent chronic pain conditions associated with insomnia are arthritis 
(primarily rheumatoid), spinal pain (including low back pain), and 
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fibromyalgia(194-196). Although preclinical models of osteoarthritis(165, 197-
199), sciatic nerve injury(161, 200-202), and inflammatory pain(203) have been 
used to determine the impact of chronic pain on sleep, none of these conditions 
constitute musculoskeletal pain. To the best of our knowledge, no preclinical 
models have been used to investigate the effect of chronic musculoskeletal pain 
on sleep. Changes in rodent sleep in models of osteoarthritis, sciatic nerve injury, 
and inflammatory pain include increased wakefulness, decreased rapid eye 
movement (REM) sleep and non-rapid eye movement (NREM) sleep, and an 
increased latency to sleep onset(160, 161, 197, 199, 203). Given the clinical 
correlations between some musculoskeletal pain conditions and altered sleep, 
we hypothesized that musculoskeletal sensitization would disrupt sleep of 
rodents. To test this hypothesis, we quantified sleep of mice before and after 
musculoskeletal sensitization. We now report that musculoskeletal sensitization 
fragments the sleep of mice and alters some facets of the sleep EEG. 
METHODS 
Animals 
Adult male C57BL/6J mice (22–25 g) were purchased from the Jackson 
Laboratory (Bar Harbor, ME). All mice were maintained on a 12:12 h light:dark 
cycle at 27°C with ad libitum access to food and water. All procedures using mice 
in these studies were approved in advance by the University of Washington 
Institutional Animal Care and Use Committee (IACUC), in accordance with the 
US Department of Agriculture Animal Welfare Act and the National Institutes of 




Musculoskeletal sensitization using acidified saline injections has 
previously been used to study aspects of the muscle pain associated with chronic 
pain conditions, including chronic widespread pain and fibromyalgia, in 
rodents(114, 115). Briefly, this protocol involves 2 unilateral injections into the 
gastrocnemius muscle spaced 5 days apart of either normal (pH 7.2, control) or 
acidified (pH 4.0) saline. When acidified saline is injected using this protocol, a 
robust bilateral secondary mechanical hypersensitivity at the hindpaws develops 
and persists at least 4 weeks(114, 115). In each experiment, mice were 
randomized into groups injected with either normal saline or acidified saline. At 
the time of injection, mice were briefly anesthetized using isoflurane, a hind leg 
cleaned using alcohol, and 20 µL of normal or acidified saline injected into the 
gastrocnemius muscle using a 31g needle. All animals were immediately 
returned to their home cage and observed by the investigator until fully 
ambulatory.  
Mechanical Hypersensitivity Testing 
The von Frey filament test is used to measure sensitivity to a non-noxious 
punctate pressure stimulus. All habituation and testing took place at light onset 
and was completed during the first 2 h of the light period. Mice were habituated 
to a galvanized steel mesh testing platform for a minimum of 60 min for 3 days 
prior to baseline testing. On testing days, mice were given a minimum of 30 min 
(or until quiet) to habituate to the testing platform. Calibrated filaments (0.07, 
0.45, and 1.45 g pressure deflection) were presented in ascending order to the 
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glabrous skin of the hindpaw until they bowed slightly(117). Hindpaws were 
alternated until a total of 5 presentations per filament per paw was reached. 
Testing continued until all 3 filaments had been presented with a minimum of 1-
min break between filament presentations. If mice became active, testing was 
suspended until mice were quiet before continuing. Positive responses were 
recorded when mice retracted the paw in response to the filament.  
Experimental Design and Clinical Health Monitoring 
A total of 30 C57B/L6 mice were used in this study. A subset (n = 14) of 
mice was implanted with telemetry units to record EEG and body temperature, 
which were used to determine sleep state (see later). Surgically implanted mice 
were given three weeks of recovery before the study began. All mice, irrespective 
of whether they were surgically implanted or uninstrumented, were 9-12 weeks at 
the time von Frey testing began. All mice underwent 3 days of baseline von Frey 
testing to determine mechanical sensitivity. For mice implanted with telemetry 
units, 2 days of baseline EEG and body temperature recordings were collected 
prior to sensitization injections. All mice were twice injected with either normal (n 
= 14 total; n = 6 instrumented) or acidified saline (n = 16 total; n = 8 
instrumented), 5 days apart as described above. Mechanical sensitivity was 
assessed at baseline (before any injections) and 1, 3, 7, 14, 21 days after the 
second sensitization injection. EEG and body temperature were recorded from 
mice instrumented with telemeters for the duration of the protocol.  
Daily food consumption, water consumption, and body weight were 
recorded at light onset throughout the experimental protocol. These measures 
25 
 
provided an assessment of the impact of musculoskeletal sensitization on the 
overall health of the animal. 
Surgical Procedures 
Mice that were implanted with the telemeters were deeply anesthetized 
with isoflurane (4% induction, 2% maintenance) and surgically implanted with 
telemeters (ETA10-F20, Data Sciences International, Minneapolis, MN) to permit 
monitoring of the electroencephalogram (EEG), core body temperature (CBT) 
and activity as previously reported(30, 204). Transmitter leads were passed 
subcutaneously to the base of the skull and attached to stainless steel screws 
(#80 × 1/8 in., Small Parts, Miami Lakes, FL) placed bilaterally over frontal and 
parietal cortices. These screws served as EEG recording electrodes. Mice were 
injected subcutaneously with Penicillin G Procaine (0.1 to 0.2 mL, 300,000 
units/mL) immediately after surgery to reduce risk of infection. Perioperative pain 
management consisted of providing ibuprofen (0.2 mg/mL) in drinking water for 
48 h after surgery and administration of buprenorphine (0.05 mg/kg, 
subcutaneously) at the time of surgery and for 2 days following surgery, if 
needed. Lidocaine and triple antibiotic ointment were applied topically at the 
incision site immediately after surgery. Mice were monitored during recovery from 
anesthesia until ambulatory and were then transferred to recording cages for 
recovery and habituation. 
Physiological Monitoring and Data Acquisition 
Signals from telemeters were fed to an analog converter (DSI ART 
Analog-8 CM) that converted EEG and temperature signals to voltages using a 
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transmitter-specific calibration factor provided by DSI. The output from the 
converter was captured by an AD board (model PCI-3033E, National 
Instruments) that re-digitized the data at 128 Hz with 16-bit precision. 
Temperature voltages were converted to engineering units by regression using 
calibration coefficients specific for each transmitter. General cage activity was 
detected using infrared sensors. All signals (EEG, core body temperature, and 
cage activity) were stored as binary files until further processing. 
During acquisition, the EEG was digitally filtered using Chebyschev filters 
with 3rd order coefficients into delta (0.5 - 4.5 Hz) and theta (6.0 - 9.0) Hz 
frequency bands. These filtered EEG signals were integrated over 1-s periods 
and stored as part of the binary file structure. Arousal state designations were 
made on the basis of visual inspection of the recordings using custom software 
(ICELUS, M. Opp, University of Michigan) written in LabView for Windows 
(National Instruments) as previously described(30, 204). Briefly, wakefulness 
(W), NREM (NREM) sleep, or REM (REM) sleep was determined for each 10-s 
epoch of the recording period based on the EEG, integrated delta and theta 
frequency components of the EEG, and general cage activity. Any epoch 
containing either movement artifacts or electrical noise was tagged and excluded 
from subsequent spectral analyses. The raw, non-integrated EEG signals were 
processed offline using fast Fourier transforms (FFT) to yield power spectra 
between 0.5 and 40 Hz in 0.5 Hz frequency bins. These spectra were computed 
by averaging the 5 consecutive 2-s EEG segments comprising each 10-s epoch. 
The resulting spectrum was matched to state to provide state-specific spectra. 
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Spectra were normalized as a percentage of total power across all frequencies 
for specific behavioral states within the 12-h light or dark period. 
The extent to which sleep was consolidated or fragmented was 
determined by evaluating the number of transitions from one arousal state to the 
next. These determinations were made irrespective of arousal state designation 
and without the use of arbitrary criteria for sleep architecture parameters. 
Latency to REM sleep was defined and recorded as the time in minutes from light 
onset to the first REM sleep bout consisting of a minimum of 2 consecutive 
epochs (20 s) of REM sleep. 
Statistical Analysis 
Statistical analyses were performed using SPSS for Windows. All data are 
presented as mean ± standard error of the mean (SEM). To determine the impact 
of manipulations across time, analyses were restricted to within-group (normal 
saline, acidified saline) comparisons for time spent in each behavioral state, core 
body temperature, food and water consumption, and body weights. These within-
group comparisons were made by means of a general linear model for repeated 
measures using a within subjects factor of time. To determine if there was an 
effect of intramuscular injections on these parameters, a general linear model for 
repeated measures with between-subjects factor of treatment (normal saline, 
acidified saline) was used.  
To determine if there was an effect of intramuscular injections on 
mechanical sensitivity, comparisons were made by evaluating the response 
incidence ([response per filament/5 possible responses] × 100) data for each 
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paw (ipsilateral, contralateral to intramuscular injection) from each individual 
monofilament, as well as a total response incidence ([Total responses per 
paw/15 possible responses] × 100). Repeated-measures ANOVA with between-
subjects factor of treatment (control, acidified) and a within-subjects factor of time 
(day of experimental protocol) was used to test ipsilateral and contralateral paw 
data. An α level of P ≤ 0.05 was accepted for all statistical tests as indicating 
significant departures between the groups across the testing period.  
RESULTS 
Bilateral Mechanical Hypersensitivity 
Unilateral injections of acidified saline spaced 5 days apart produced 
mechanical hypersensitivity at the hindpaws relative to control animals injected 
with normal saline (Fig. 1). This hypersensitivity was detected across all 3-
filament pressures and manifest as a significant increase in response incidence 
to von Frey testing that was apparent on day 3 and continued across all 21-
protocol days. Total responsiveness to filaments of mechanically sensitized 
animals was significantly increased for the 3-week testing period when compared 
with control mice (between groups) and pre-injection baseline (within groups).  
Sleep State Transitions 
The number of state transitions during the baseline recording period did 
not significantly differ among mice subsequently randomized into the two 
treatment groups (Table 1). Within subjects analysis revealed modest, yet 
statistically significant increases in the number of state transitions for control 
mice only during the light period across all recording days. However, mice 
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injected with acidified saline and subsequently sensitized exhibited an increase in 
the number of state transitions during both the light and dark period post-
injection. Furthermore, between subjects analysis revealed that experimental 
mice with musculoskeletal sensitization manifest a greater number of state 
transitions than control mice at all time points assessed during the protocol 
(Table 1). 
Sleep Duration 
The amount of NREM and REM sleep during the baseline recording 
period did not differ among mice subsequently randomized into the 2 treatment 
groups (Table 1). Within subjects analyses did not reveal a significant change in 
either NREM or REM sleep duration during the recording period for either 
injection group (Table 1). Similarly, between subjects analyses did not reveal a 
significant impact of musculoskeletal sensitization on NREM or REM sleep time 
(Table 1). Latency to REM sleep increased significantly for mice injected with 
acidified saline. The average REM sleep latency increased from 21 min at 
baseline to 75 min after musculoskeletal sensitization. 
NREM Delta Power and Spectral Analysis 
EEG spectral characteristics were analyzed from recordings obtained at 
baseline and days 2, 8, 15, and 20 after the second intramuscular injection. Delta 
power during NREM is a common measure of sleep intensity(205, 206), with 
NREM delta power increasing during recovery sleep after periods of prolonged 
wakefulness(24). Because of inter-animal variations in the EEG, all analyses 
were performed on values normalized relative to the 12 hour average NREM 
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delta power for the light and dark period ([Hourly value / 12h period 
average]*100)(23). At pre-injection baseline, normalized delta power during 
NREM sleep during the 12-h light or dark period did not significantly differ 
between mice subsequently randomized to injection groups. Within subjects 
analysis did not reveal a significant change in NREM delta power within injection 
groups across the recording period. Similarly, between subjects analysis did not 
reveal significant effects of musculoskeletal sensitization on normalized NREM 
delta power (Table 1).  
State-specific EEG power spectra were normalized as a percentage of 
total power across all frequencies for specific behavioral states within the 12-h 
light or dark period. Statistical analyses were performed on bins in the delta (0.5 - 
4.5 Hz) and theta (6.0 - 9.0 Hz) frequency bands for NREMS and REMS, 
respectively. Although statistical significance was not achieved across the 
frequency bands, there was a significant increase in the peak theta frequency of 
acidified saline injected mice during dark period REM sleep (Fig. 3). 
Food Consumption, Water Consumption, Body Weight, and Core Body 
Temperature 
Daily food consumption, water consumption, and body weight were not 
significantly impacted by intramuscular acidified saline injections (data not 
shown). Repeated-measures analysis did not reveal a significant effect of 
manipulation (normal saline, acidified saline) on these parameters.  
Pre-injection baseline core body temperature did not differ among mice 
that were subsequently randomized to the injection groups. No significant effect 
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of injection was detected by repeated measures analysis within subjects or 
between injection groups (Table 1).  
DISCUSSION 
Approximately 20% of Americans report that pain or physical discomfort 
disrupts their sleep at least a few nights a week(207), and patients with chronic 
pain conditions often report sleep disruption as a comorbidity to their pain(157, 
208). Although three of the most prevalent types of chronic pain in the United 
States are musculoskeletal; low back pain, neck pain, and facial pain(4), most 
preclinical studies of pain have focused on neuropathic or inflammatory pain(158, 
159). Improving sleep can reduce next day pain(193), especially in patients with 
ongoing musculoskeletal pain(175). Persons with musculoskeletal disorders, 
including pain, have a lower quality of life as compared with other chronic 
ongoing health conditions(102). Sleep affects a wide range of homeostatic 
biological functions such as mood regulation, cardiovascular function, and 
cognitive functions including decision making, memory, and attention(1). The 
negative impact of musculoskeletal pain on sleep may in turn influence the 
collective well-being of the patient more than a chronic pain state independent of 
sleep disruption. 
The novel finding of this study is that musculoskeletal sensitization 
fragments sleep of mice without altering the total amount of time spent in NREM 
sleep, REM sleep, or wakefulness. Furthermore, musculoskeletal sensitization 
does not impact the clinical health of mice as evidenced by measures of body 
weight, food and water consumption and body temperature. Our observations 
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that acidified saline injections into mice induce bilateral secondary mechanical 
hypersensitivity replicate findings in the literature(114, 115), and suggest this 
model may be of utility for studies of interactions between sleep and 
musculoskeletal sensitization.  
In this present study, musculoskeletal sensitization did not alter the 
amount of time spent in NREM or REM sleep. The literature is varied with 
respect to the extent to which sleep amounts are disrupted during chronic 
pain(161, 164). For example, chronic constriction injury (CCI), in which a 
surgically implanted suture constricts the sciatic nerve and produces allodynia at 
the hindpaw, in one study is reported to transiently alter sleep of rats(161), an 
effect that was most robust during the first 10 days after nerve constriction. 
Another study using the same model in rats reported no changes to sleep(164). 
Differences in findings between these studies may be due to the post-injury time 
course selected for recording. In the first study sleep state was monitored 
continuously 21 days after surgery(161), whereas the study that saw no change 
recorded for single days with the first occurring 13 days post-surgery(164). This 
difference in time course suggests that CCI may have resulted in significant 
changes in sleep during the first 10 days post-surgery as previously reported, but 
beginning recordings on day 13 may have missed this significant change.  
It is also possible that subpopulations of rodents differ in their 
susceptibility to chronic pain(166, 209, 210). Monassi and colleagues identify 3 
distinct phenotypes of responders after CCI; animals that manifest pain with 
persistent disability, those that exhibit pain with only transient disability, and 
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those that indicate pain, but no disability(166). In these studies, all rats 
developed sensitivity to mechanical and cold stimuli to the same degree, but 
exhibited different phenotypic changes in sleep. Rats exhibiting pain with 
persistent disability spent less time in NREM sleep and increased wakefulness 
during both the light and dark periods, an effect that persisted for the 8-day follow 
up period after CCI. Rats with pain and only transient disability spent less time in 
NREM sleep and increased wakefulness, but only during the light period, and this 
effect normalized by the end of the 8-day recording period. Sleep was not altered 
in rats that exhibited pain without disability(166).  
To investigate a role for astrocytes as mediators of pain and disability after 
CCI, the periaqueductal gray (PAG) was stained for glial fibrillary acid protein 
(GFAP), a marker of activated astrocytes. Increased staining for GFAP was 
detected in the lateral and caudal ventrolateral columns of the PAG in rats 
exhibiting pain with persistent disability(210). The anatomical specification of this 
upregulation of GFAP suggests that afferents from both the spinal column and 
nucleus of the solitary tract may be critical as the ventrolateral PAG is the site of 
termination. Furthermore, mRNA expression for markers of cell death in the PAG 
is upregulated in rats with pain and persistent disability(209). Because the PAG 
is a brain region involved in the regulation of sleep(107, 211, 212) and pain(108, 
211), data from these collective studies indicate that the PAG may serve as a 
critical site of integration for interactions between pain and sleep.  
Although the PAG may be functionally implicated in regulating sleep and 
pain, the PAG has limited direct projections to the spinal cord(213). The PAG 
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does however, have direct projections to the rostral ventral medulla (RVM), which 
in turn projects to the spinal cord(214). The RVM is involved in pain 
transmission(108, 214, 215) and is implicated in mediating muscle 
sensitivity(119, 216, 217). Microinjections of local anesthetic(119) or NMDA 
receptor antagonists(217) into the RVM after bilateral mechanical hypersensitivity 
has developed reverses mechanical hypersensitivity. After one intramuscular 
injection with acidified saline, glycine concentrations in the RVM are 
reduced(216). Following the second acidified saline injection, but not the first, 
glutamate concentration increase in the RVM(216). The RVM contributes to the 
maintenance of hypersensitivity in the musculoskeletal sensitization model 
through regulation of neurotransmitter release, changes in NMDA receptor 
expression, and changes in neuronal excitability(110, 216, 217). As such, data 
support the hypothesis that the RVM and PAG may independently or 
synergistically contribute to the sleep fragmentation and mechanical 
hypersensitivity associated with musculoskeletal sensitization. Future 
experiments will test this mechanistic hypothesis. 
Sleep fragmentation, characterized by an increased number of transitions 
between arousal states, is frequently reported in preclinical models of chronic 
pain. Several studies report changes in sleep of rats using an adjuvant-induced 
arthritis model(165, 197). Sleep of arthritic rats is characterized by increased total 
number of sleep and wakefulness bouts, increased microarousals, decreased 
NREM and REM sleep duration, and a reduction in sleep efficiency(165, 197). 
Sleep fragmentation has also been recorded in both male and female rats with 
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experimental osteoarthritis characterized by reduced NREM and REM sleep and 
reduced sleep efficiency(198). Arthritis induced by intra-articular knee injections 
of uric acid produces lasting increases in wakefulness, reductions in REM sleep, 
and REM bout numbers of rats(163). Sleep is also fragmented during orofacial 
pain, a model in which chronic pain is induced by injecting Freund’s adjuvant into 
the masseter muscle. Under these conditions, sleep efficiency is reduced and the 
amount of time spent in wakefulness is increased(218, 219). In mice with 
experimental neuropathic pain induced by sciatic nerve ligation, NREM sleep is 
suppressed and wakefulness increased for at least 28 days following 
surgery(200). The common thread among these studies of chronic pain using 
different preclinical models is one of fragmented sleep, usually accompanied by a 
change in sleep duration. Our findings of increased state transitions during 
musculoskeletal sensitization are consistent with these previous observations 
and contribute to the growing literature of the manner in which sleep is disrupted 
during chronic pain.  
Fibromyalgia is a chronic condition of unknown etiology characterized by 
widespread musculoskeletal pain and sleep disruption(220). Among chronic pain 
conditions, fibromyalgia is unique because un-refreshing sleep is a diagnostic 
factor(221, 222). Patients often complain of non-restorative sleep, insomnia, 
early morning awakenings, and overall poor sleep quality(223-225). The pain that 
is experienced by fibromyalgia patients correlates with quality of sleep, such that 
diminished subjective sleep quality is associated with enhanced pain(226, 227). 
Changes in the EEG of patients with fibromyalgia are characterized by an 
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intrusion of alpha waves into the NREM sleep that corresponds with next day 
pain(224, 228), although recent studies do not replicate these findings(229). Our 
study demonstrates changes in theta frequency components of the EEG spectra 
during REM sleep that persist for at least 20 days post sensitization. At present, 
the functional significance of altered EEG spectra during musculoskeletal 
sensitization in this model remains to be determined. 
The economic costs and personal impact of chronic pain and sleep 
disruption on quality of life underscore the need for additional treatment options. 
Clinical surveys identify that subjectively restorative sleep reduces next day pain, 
especially in patients with musculoskeletal pain(175). Conversely, reduction of 
daytime pain does not predict subsequent restorative sleep(175), and a lack of 
restorative sleep could further exacerbate pain. These relationships between 
sleep and pain suggest a “vicious cycle” that perhaps may be broken by focusing 
on manipulation of sleep, not pain, as a critical target for intervention. In patients 
with chronic pain and sleep disturbance, it may be possible to alleviate or reduce 
pain by effective interventions to improve sleep quality using targeted 
pharmacological treatments, behavioral treatments, or a combined approach. 
Indeed, recent studies demonstrate that cognitive behavioral therapy to treat 
insomnia in patients with fibromyalgia and other chronic pain conditions also is 
effective in reducing pain(230, 231). 
Our data demonstrate that musculoskeletal sensitization using acidified 
saline injections fragments sleep of mice without reducing amounts of NREM or 
REM sleep. Food and water intake, as well as body weight, are not altered during 
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musculoskeletal sensitization in this model. Collectively, our data support findings 
in the clinical literature that musculoskeletal pain fragments sleep. Our present 
results are an initial attempt to determine the extent to which sleep is disrupted 
during musculoskeletal sensitization. These results demonstrate a relationship 
between musculoskeletal sensitization and sleep, yet do not provide knowledge 
about mechanisms underlying these interactions. The similarity between the 
patient reported experience of sleep disruption during musculoskeletal pain and 
sleep fragmentation of mice during musculoskeletal sensitization provides a 
framework to begin investigating the mechanisms underlying relationships 








































Figure 1. Musculoskeletal sensitization enhances bilateral responses to 
von Frey testing. 
Mice injected with acidified saline (n = 16) exhibit mechanical hypersensitivity for 
at least 21 days, whereas mechanical hypersensitivity does not develop in mice 
injected with normal pH saline (n = 14). Responsiveness to von Frey filaments 
are plotted as mean ± SEM total response incidence percent ([total responses / 
total filament presentations] × 100) per paw. * p < 0.05 vs. normal pH saline 
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Figure 2. Sleep is fragmented after musculoskeletal sensitization with 
acidified saline. 
The total number of transitions/h is plotted across the 24-h light/dark period only 
for animals injected with acidified saline (n = 8). Symbols are the mean ± SEM for 
pre-injection baseline and for 20 days after mechanical hypersensitivity is 
induced. Acidified saline injections fragment of sleep during the light period. (B) 
The average number of transitions/h during the 12-h light or dark period is plotted 
for pre-injection baseline (BL), and for days 2, 8, 15, and 20 after mechanical 
hypersensitivity is induced.  Values are the mean ± SEM for n = 8 mice. (C) 
Representative hypnograms from one mouse obtained during pre-injection 
baseline, and at days 2, 8, 15, and 20 after induction of mechanical 
hypersensitivity. Hypnograms are from a 1-h recording 10 h after light onset 
during each of the days depicted. W-Wakefulness, N-NREM, R-REM sleep  # p ≤ 














































































Figure 3. State-specific electroencephalogram (EEG) power spectra are 
altered during musculoskeletal hypersensitivity.   
State-specific EEG power spectra were obtained from mice injected with either 
normal pH saline (n = 6; thin grey lines) or acidified pH saline (n = 8; thick black 
lines). Data presented were obtained 20 days following musculoskeletal 
sensitization (or control injections). Spectra were normalized as a percentage of 
total power within each frequency band during the 12-h light or dark period and 
are plotted as mean ± SEM for each frequency bin. Statistical analyses were 
performed on bins comprising the delta frequency band (0.5 - 4.5 Hz) and the 
theta frequency band (6.0-9.0 Hz) for NREMS and REMS, respectively. A 
significant change was detected between the peak theta frequency during the 
dark period for NREM sleep between injection groups on day 20. * p ≤ 0.05 vs. 
normal pH saline injection. 
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LIGHT DARK LIGHT DARK LIGHT DARK LIGHT DARK LIGHT DARK
52.5 ± 2.5 33.0 ± 2.3 51.8 ± 1.9 32.3 ± 2.2 53.4 ± 2.0 28.5 ± 1.8 53.7 ± 2.0 31.8 ± 2.0 55.8 ± 2.0 31.1 ± 2.0
57.2 ± 1.7 31.3 ± 2.5 49.2 ± 1.8 32.6 ± 2.1 48.8 ± 2.2 31.8 ± 2.0 50.6 ± 2.0 31.0 ± 1.9 50.6 ± 2.0 34.2 ± 1.8
REM (% recording time)
5.1 ± 0.3 3.3 ± 0.4 5.2 ± 0.3 2.1 ± 0.3 5.2 ± 0.4 2.1 ± 0.3 5.2 ± 0.3 2.0 ± 0.3 5.6 ± 0.3 1.7 ± 0.3
3.9 ± 0.3 2.3 ± 0.1 5.0 ± 0.4 2.0 ± 0.4 5.1 ± 0.4 1.8 ± 0.3 4.7 ± 0.4 1.7 ± 0.3 5.7 ± 0.4 1.7 ± 0.3
WAKEFULNESS (% recording time)
42.4 ± 2.8 63.6 ± 2.7 43.0 ± 2.2 65.5 ± 2.4 42.8 ± 1.8 70.0 ± 2.1 41.1 ± 2.2 66.2 ± 2.2 38.6 ± 2.2 67.1 ± 2.2
38.9 ± 1.9 66.4 ± 2.7 45.8 ± 2.0 65.4 ± 2.4 46.1 ± 2.4 66.4 ± 2.2 44.7 ± 2.1 67.3 ± 2.1 43.6 ± 2.2 64.1 ± 2.0
T CORE (˚C)
36.5 ± 0.11 37.1 ± 0.04 36.0 ± 0.06 37.1 ± 0.10 36.2 ± 0.08 37.1 ± 0.10 35.8 ± 0.08 37.0 ± 0.07 35.7 ± 0.09 37.1 ± 0.07 
35.9 ± 0.10 37.1 ± 0.06 36.3 ± 0.09 37.1 ± 0.10 36.0 ± 0.10 37.2 ± 0.06 35.8 ± 0.09 37.0 ± 0.07 35.9 ± 0.09 37.1 ± 0.05
DELTA PWR (arbitrary unit)
.87813 ± 0.031 1.1358 ± 0.025 .90411 ± 0.019 1.108 ± 0.023 0.8884 ± 0.023 1.120 ± 0.025 0.8958 ± 0.028 1.113 ± 0.023 0.9506 ± 0.029 1.051 ± 0.027
.90586 ± 0.011 1.1130 ± 0.016 .94988 ± 0.017 1.053 ± 0.015 0.9560 ± 0.017 1.045 ± 0.015 .9396 ± 0.016 1.063 ± 0.016 0.9534 ± 0.017 1.0433 ± 0.014
TRANSITIONS (average # per hour)
23.5 ± 1.5 18.3 ± 1.5 27.8 ± 1.3 
#
17.0 ± 1.2 29.1 ± 1.5 
#
17.1 ± 1.2 30.7 ± 1.6 
#
18.1 ± 1.3 28.5 ± 1.5 
#
16.4 ± 1.2
25.5 ± 1.0 17.8 ± 1.4 44.9 ± 2.4




NREM (% recording time)
BASELINE DAY 2 DAY 8 DAY 15
 
Table 1. Sleep duration, core temperature, normalized delta power, and 
sleep state transitions across the recording period.   
Sleep duration, core body temperature, normalized delta power, and arousal 
state transitions averaged during the light and dark period. Normal (n=6) and 
acidified (n=8). NREM, REM and Wakefulness are presented as a percentage of 
total recording time for the light or dark period respectively. Core body 
temperature is presented in ˚C. Delta power is normalized relative to the 12h 
average per mouse. State transitions are presented as the average number of 
state transitions per hour during the light or dark period. T Core- Core body 






SLEEP FRAGMENTATION EXACERBATES MECHANICAL 
HYPERSENSITIVITY AND ALTERS SUBSEQUENT SLEEP-WAKE 




Study Objectives:  Sleep deprivation or sleep disruption enhances pain 
in human subjects.  Chronic musculoskeletal pain is prevalent in our society, and 
constitutes a tremendous public health burden.  Although pre-clinical models of 
neuropathic and inflammatory pain demonstrate effects on sleep, few studies 
focus on musculoskeletal pain.  We previously reported that musculoskeletal 
sensitization alters sleep of mice.  In this study we hypothesize that sleep 
fragmentation during the development of musculoskeletal sensitization will 
exacerbate subsequent pain responses and alter sleep-wake behavior of mice. 
Design:  This is a pre-clinical study using C57BL/6J mice to determine the 
impact of sleep fragmentation combined with musculoskeletal sensitization on 
behavioral outcomes. 
Methods:  Musculoskeletal sensitization, a model of chronic muscle pain, 
was induced using two unilateral injections spaced five days apart of acidified 
                                            
2
 The work presented in this chapter are under review for publication: Sutton, B.C. & Opp, 
M.R. Sleep fragmentation exacerbates mechanical hypersensitivity and alters subsequent sleep-
wake behavior in a mouse model of musculoskeletal sensitization. SLEEP. 
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saline (pH 4.0) into the gastrocnemius muscle.  Musculoskeletal sensitization 
manifests as mechanical hypersensitivity as determined by von Frey filament 
testing at the hindpaws.  Sleep fragmentation took place during the consecutive 
12h light periods of the 5 days between intramuscular injections.  EEG and body 
temperature were recorded from some mice at baseline and for three weeks after 
musculoskeletal sensitization.  Mechanical hypersensitivity was determined at 
pre-injection baseline and on days 1, 3, 7, 14, and 21 after sensitization.  Two 
additional experiments were conducted to determine the independent effects of 
sleep fragmentation and musculoskeletal sensitization on mechanical 
hypersensitivity. 
Results:  Five days of sleep fragmentation by itself did not induce 
mechanical hypersensitivity, whereas sleep fragmentation combined with 
musculoskeletal sensitization resulted in prolonged and exacerbated mechanical 
hypersensitivity responses.  Sleep fragmentation combined with musculoskeletal 
sensitization had an impact on subsequent sleep of mice as demonstrated by 
increased sleep-wake state transitions during the light and dark periods; changes 
in NREM sleep, REM sleep and wakefulness; and altered delta power during 
NREM sleep.  These effects persisted for at least three weeks post-sensitization.    
Conclusions:  Our data demonstrate that sleep fragmentation combined 
with musculoskeletal sensitization exacerbates the physiological and behavioral 
responses of mice to musculoskeletal sensitization, including mechanical 
hypersensitivity and sleep.  These data contribute to a growing literature 
demonstrating bi-directional relationships between sleep and pain.  The 
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prevalence and incidence of insufficient sleep and pathologies characterized by 
chronic musculoskeletal pain are increasing in the United States.  These 
demographic data underscore the need for research focused on insufficient sleep 
and chronic pain so that the quality of life for the millions of individuals suffering 
these conditions may be improved. 
INTRODUCTION 
Sleep loss negatively impacts homeostatic functions including metabolism, 
cognition, emotional regulation, immune function, cardiovascular function, and 
pain(1, 9, 176, 232-234).  In the United States nearly 30% of the adult population 
reports insufficient sleep(207) and roughly 70 million Americans have a 
diagnosed sleep disorder(207).  Sleep disorders, including insomnia, narcolepsy, 
and sleep apnea, fragment or restrict sleep(235-237).  Experimental deprivation 
or restriction of sleep in humans and rodents enhances pain(171, 173, 180, 183, 
238, 239).  Subjectively sleepy persons have reduced pain thresholds compared 
to well-rested individuals(192), and chronic pain is the most frequent co-morbidity 
associated with primary insomnia(169).  Epidemiological studies identify 
subjectively poor sleep quality as an independent risk factor for the development 
of chronic pain conditions, especially those characterized by musculoskeletal 
pain(55, 194).   
Musculoskeletal pain is prevalent in our society, with low back pain, neck 
pain, and facial pain(4) constituting a major public health burden.  Arthritis 
(primarily rheumatoid), spinal pain (including low back pain), and fibromyalgia, all 
musculoskeletal, are the most prevalent chronic pain conditions associated with 
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insomnia(194-196).  Data derived from pre-clinical studies of rodents support 
clinical findings that sleep loss reduces pain threshold(180, 182, 183).  In a 
rodent model of musculoskeletal pain, musculoskeletal sensitization induces 
long-lasting mechanical hypersensitivity characterized by increased 
responsiveness to mechanical stimuli(114-116).  We recently reported that sleep 
of mice in which musculoskeletal sensitization has been induced is 
fragmented(116).  In this study, we hypothesize that sleep fragmentation during 
the period when musculoskeletal sensitization develops will exacerbate the 
effects of musculoskeletal sensitization.  To test this hypothesis, we fragmented 
sleep of mice, induced musculoskeletal sensitization, and determined the impact 
on subsequent sleep-wake behavior and mechanical hypersensitivity.  We now 
report that sleep fragmentation combined with musculoskeletal sensitization 
exacerbates for prolonged periods mechanical hypersensitivity and alters 
multiple facets of mouse sleep. 
METHODS 
Animals 
Adult male C57BL/6J mice (4-6 weeks of age; 25 g) were used in this 
study.  All mice were purchased from Jackson Laboratory (Bar Harbor, ME), and 
maintained on a 12:12 h light:dark cycle at 27 °C with ad libitum access to food 
and water.  All procedures using mice in these studies were approved in advance 
by the University of Washington Institutional Animal Care and Use Committee 
(IACUC), in accordance with the US Department of Agriculture Animal Welfare 
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Act and the National Institutes of Health policy on Humane Care and the Use of 
Laboratory Animals. 
Clinical health of mice was monitored daily at light onset and consisted of 
measures of food consumption, water consumption, and body weight.  These 
data were collected throughout the surgical recovery period and for the duration 
of the protocols.   
Musculoskeletal Sensitization 
Musculoskeletal sensitization was induced by two unilateral injections of 
acidified saline into the gastrocnemius muscle.  The injections were spaced five 
days apart and consisted of either normal (pH 7.2; control) or acidified (pH 4.0) 
saline.  Acidified saline injections in this protocol producee a robust bi-lateral 
secondary mechanical hypersensitivity at the hindpaws that lasts at least 4 
weeks(114-116).  At the time of injection, mice were briefly anesthetized using 
isoflurane, a hind leg cleaned using alcohol, and 20 µL of normal or acidified 
saline injected into the gastrocnemius muscle using a 31g needle.  All animals 
were immediately returned to their home cage and observed by the investigator 
until fully ambulatory.  
Mechanical Hypersensitivity Testing 
The von Frey filament test measures sensitivity to a non-noxious punctate 
pressure stimulus using calibrated monofilaments.  Determination of mechanical 
hypersensitivity was done as previously reported(116).  Briefly, mice were 
habituated to the testing procedure and the galvanized steel mesh testing 
platform for a minimum of 60 minutes each day for 3 days prior to obtaining 
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baseline values.  On testing days, mice were placed on the testing platform for a 
minimum of 30 minutes (or until quiet).  Calibrated filaments (0.07, 0.45, & 1.45 g 
pressure deflection) were then presented in ascending order to the glabrous skin 
of the hindpaws until they bowed slightly(116, 117).  Hindpaws were alternated 
until a total of 5 presentations per filament per paw were reached.  Each of the 3 
filaments were presented with a minimum 1-minute break between filament 
presentations.  Positive responses were recorded when mice retracted the paw 
in response to the filament pressure. If mice became active, testing was 
suspended until they were quiet.  All testing was done during the first 2 hours of 
the light period. 
Sleep Fragmentation 
All animals undergoing sleep fragmentation were placed into the sleep 
disruption devices one day prior to the start of the sleep fragmentation protocol.  
The sleep disruption device consists of a circular Plexiglas chamber divided to 
form two compartments(65).  The floor of the chamber is a motorized disc that 
rotates for specific durations as selected by the investigator.   
Individual animals were placed into separate compartments prior to device 
habituation.  Device habituation consisted of rotation of the disc for 8 seconds 
once every 30 minutes during one 12h light period of the 12:12 light:dark cycle.  
No disc rotation occurred during the dark period, during which mice were left 
undisturbed.  Intramuscular injections and the beginning of sleep fragmentation 
began at light onset the day after habituation.  Sleep was fragmented for 5 days 
by disc rotations that lasted for 8 seconds and occurred every 30 seconds, on 
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average, during the 12h light periods.  During the 12h dark periods, the disc did 
not rotate and mice were free to behave normally.  The direction of disc rotation 
and exact inter-rotation interval were computer-randomized to prevent behavioral 
adaptation of the animals to the rotations.  Each disc rotation was greater than 
180 degrees to ensure the mouse had to move to avoid bumping into the center 
divider of the chamber.  We have demonstrated that this method of fragmenting 
sleep of mice is effective in protocols lasting up to 9 days(65). 
Surgical Procedures 
Mice from which recordings of the electroencephalogram (EEG) were to 
be obtained were deeply anesthetized with isoflurane (4% induction, 2% 
maintenance) and surgically implanted with telemeters (ETA10-F20, Data 
Sciences International, Minneapolis, MN).  As previously described(30, 116, 
240), transmitters were implanted in the peritoneum and leads were passed 
subcutaneously to the skull and attached to stainless steel screws (#80 × 1/8 in., 
Small Parts, Miami Lakes, FL) placed bilaterally over frontal and parietal cortices.  
These screws served as EEG recording electrodes.  Mice were injected 
subcutaneously with Penicillin G Procaine (0.1 to 0.2 mL, 300,000 units/mL) 
immediately after surgery to reduce risk of infection.  Perioperative pain 
management consisted of ibuprofen in drinking water (0.2 mg/ml; beginning 24 h 
before surgery and continuing for 48 h after surgery) and administration of 
buprenorphine (0.05 mg/kg, subcutaneously) at the time of surgery and for two 
days following surgery, if needed.  Lidocaine and triple antibiotic ointment were 
applied topically at the incision site immediately after surgery.  Mice were 
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monitored until ambulatory and then transferred to recording cages for recovery 
and acclimation. 
Data Acquisition 
Signals from telemeters were fed to an analog converter (DSI ART 
Analog-8 CM) that converted EEG and temperature signals to voltages using 
transmitter-specific calibration factors provided by DSI.  The output from the 
converter was captured by an AD board (model PCI-3033E, National 
Instruments) that re-digitized the data at 128 Hz with 16-bit precision.  
Temperature voltages were converted by regression using calibration coefficients 
specific for each transmitter.  General activity in the cage was detected using 
infrared sensors (BioBserve, GmbH, Bonn, Germany).  Movements detected by 
the sensors were converted to a voltage output, the magnitude of which was 
directly related to the magnitude of movements detected.  All signals (EEG, core 
body temperature, and cage activity) were stored as binary files until further 
processing. 
During acquisition, the EEG was digitally filtered using Chebyschev filters 
with 3rd order coefficients into delta (0.5 - 4.5 Hz) and theta (6.0 - 9.0 Hz) 
frequency bands.  These filtered EEG signals were integrated over 1-s periods 
and stored as part of the binary file structure.  Arousal state designations were 
made with 10-s resolution on the basis of visual inspection of the recordings 
using custom software (ICELUS, M. Opp, University of Washington) written in 
LabView for Windows (National Instruments).  Arousal state was assigned for 
each 10-s interval on the basis of the EEG, body movements, and integrated 
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delta and theta frequency values using previously published criteria(116, 204, 
240).  Any epoch during which the EEG contained either movement artifacts or 
electrical noise was tagged and excluded from subsequent spectral analyses. 
The raw, non-integrated EEG signals were processed offline using fast Fourier 
transforms (FFT) to yield power spectra between 0.5 and 40 Hz in 0.5 Hz 
frequency bins. These spectra were computed by averaging the five consecutive 
2-s EEG segments comprising each 10-s epoch. The resulting spectrum was 
matched to state to provide state-specific spectra. Our primary focus in this study 
was power in the delta frequency band during NREM sleep. These values for 
delta power during NREM sleep were obtained by summing the values of all 0.5 
Hz frequency bins from 0.5 - 4.5 Hz. 
The extent to which spontaneous sleep was consolidated or disrupted was 
determined by evaluating the number of transitions from one arousal state to the 
next. These determinations were made as previously described(116, 204, 240) 
irrespective of arousal state designation and without the use of arbitrary criteria 
for sleep architecture parameters. 
Determination of the impact of sleep fragmentation on mechanical 
hypersensitivity 
Three groups of mice (n=58 total) were used in this study to determine the 
combined effects of sleep fragmentation and musculoskeletal sensitization on 
outcome measures of interest.  Mice in group 1 (n=12) were used to determine 
the impact of 5 days of sleep fragmentation per se on mechanical 
hypersensitivity.  These animals did not receive intramuscular injections.  All 
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mice underwent 3 days of habituation to the von Frey testing platform and 3 days 
of baseline von Frey testing (described earlier).  Mice were then habituated to the 
sleep disruption device, after which they were subjected to sleep fragmentation 
during the 12h light period for 5 consecutive days.  After the 5-day sleep 
fragmentation protocol, mice were housed singly under standard conditions.  Von 
Frey testing was performed at baseline (BL), on the 3rd day of sleep 
fragmentation, and days 1, 3, & 7 post-fragmentation.  
Whereas mice in group 1 were used to determine the impact of sleep 
fragmentation on mechanical hypersensitivity, mice in group 2 (n=24) were used 
to determine the effect of musculoskeletal sensitization without sleep 
fragmentation on mechanical hypersensitivity.  These mice were not 
instrumented, and were housed singly in standard caging throughout the 
experimental period.  Mice underwent habituation and baseline von Frey testing 
to determine mechanical hypersensitivity prior to experimental manipulations.  
Mice were subsequently randomized to a musculoskeletal sensitization group 
[normal saline (control animals) or acidified saline; n=12 per injection group], with 
intramuscular injections administered 5 days apart.  Mechanical hypersensitivity 
was assessed on days 1, 3, 7, 14, and 21 following sensitization.  
We previously reported results of an experiment that demonstrated the 
impact of musculoskeletal sensitization on sleep of mice(116).  Mice in that study 
were allowed spontaneous behavior during the sensitization period.  The purpose 
of this present experiment was to determine the impact of sleep fragmentation 
during the musculoskeletal sensitization period on mechanical hypersensitivity 
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and subsequent sleep-wake behavior.  Twenty two mice (group 3) were used in 
this experiment, a subset of which (n=16) was instrumented to allow 
determination of sleep-wake behavior (Figure 4).  These n=16 mice were 
implanted with telemeters to record EEG and core body temperature as 
described earlier.  After recovery, baseline recordings were obtained from mice 
implanted with telemetry units for 2 days prior to experimental manipulation.  All 
mice were habituated and underwent baseline von Frey testing for mechanical 
hypersensitivity.  For all mice used in this experiment (instrumented, un-
instrumented), sleep fragmentation started after the first intramuscular injection at 
light onset and ended at light onset 5 days later when the second sensitization 
injection was given (Figure 4).  All mice were removed from the sleep disruption 
device and returned to single housed standard caging at the end of the 5 day 
sleep fragmentation period.  Mechanical hypersensitivity was measured on days 
1, 3, 7, 14, and 21 post-sensitization.  Recordings were obtained from mice 
instrumented with telemeters for 22-days after sensitization.  Two instrumented 
mice were excluded from data analysis due to poor EEG signal quality, reducing 
the final sample size of instrumented mice to n=14 (7 mice per injection group).   
Statistical Analysis 
Statistical analyses were performed using SPSS for Windows.  All data 
are presented as mean ± standard error of the mean (SEM).  To determine the 
impact of manipulations across time, analyses were restricted to within-group 
(normal saline, acidified saline) comparisons for time spent in each behavioral 
state, core body temperature, and clinical data. These within-group comparisons 
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were made by means of a general linear model for repeated measures.  To 
determine if there was an effect of intramuscular injections on sleep, core body 
temperature, and clinical data, repeated-measures ANOVA with between-
subjects factor of treatment (normal saline, acidified saline) and a within-subjects 
factor of time (day of experimental protocol). 
To determine if there was an effect of intramuscular injections on 
mechanical sensitivity, the response incidence ([response per filament / 5 
possible responses] x 100) data for each paw (ipsilateral, contralateral) from 
each individual monofilament, as well as a total response incidence ([Total 
responses per paw/15 total possible responses] x 100) were analyzed.  
Repeated-measures ANOVA with between-subjects factor of treatment (normal 
saline, acidified saline) and a within-subjects factor of time (day of experimental 
protocol) was used to test ipsilateral and contralateral von Frey data.  An alpha 
level of p ≤ 0.05 was accepted for all statistical tests as indicating significant 
departures between the groups across the testing period.  
RESULTS 
Mechanical hypersensitivity  
Data from mice in group 1 demonstrated that sleep fragmentation by itself 
for 5 days had no significant impact on mechanical hypersensitivity (Figure 5).  
As such, sleep fragmentation by this protocol did not independently induce 
mechanical hypersensitivity.  As previously published, unilateral injections of 
acidified saline 5 days apart produced bilateral mechanical hypersensitivity at the 
hindpaws (group 2; Figure 6)(114-116).  Mechanical hypersensitivity after 
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musculoskeletal sensitization lasted at least 21 days, which was the duration von 
Frey testing lasted in this study. 
Impact of sleep fragmentation combined with musculoskeletal 
sensitization on mechanical hypersensitivity and subsequent sleep-wake 
behavior  
Whereas control mice (normal saline injections) in group 3 that were 
subjected to sleep fragmentation did not develop mechanical hypersensitivity, 
mice in which musculoskeletal sensitization had been induced by injections of 
acidified saline exhibited mechanical hypersensitivity on the first post-
sensitization day (Figure 7).  Mechanical hypersensitivity in mice subjected to the 
combined manipulations of sleep fragmentation and musculoskeletal 
sensitization persisted for 21 post-sensitization (Figure 7).  The observation that 
mechanical hypersensitivity was apparent on the first post-sensitization day in 
mice subjected to sleep fragmentation during the musculoskeletal sensitization 
period was unexpected.  Our previous studies(116) and data obtained in this 
study from mice in group 2, demonstrated that mechanical hypersensitivity does 
not manifest in this model until the 3rd post-sensitization day.  Because the only 
factor that differed in this experiment was sleep fragmentation during the 
sensitization period, we compared response incidence values obtained from mice 
in group 2 that had undisturbed sleep in their home cages during the 
sensitization period with those from mice in group 3 that had sleep fragmented 
during the sensitization period.  Direct comparison of the impact of undisturbed 
sleep or fragmented sleep on mechanical hypersensitivity is presented in Figure 
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8.  Response incidence values obtained from animals injected with normal saline 
did not differ at any time irrespective of whether or not they had been subjected 
to sleep fragmentation.  Furthermore, response incidence values did not differ 
from pre-injection baseline values, indicating that being housed on the sleep 
disruption device and being subjected sleep fragmentation per se did not induce 
mechanical hypersensitivity.  However, mice in which sleep was fragmented 
during the period of musculoskeletal sensitization developed mechanical 
hypersensitivity that was of greater magnitude than that of mice allowed 
undisturbed sleep (Figure 8).  This increased mechanical hypersensitivity 
observed in mice subjected to the combination of sleep fragmentation and 
musculoskeletal sensitization was apparent on the first post-sensitization day and 
on post-sensitization day 21 (Figure 8). 
In addition to its impact on mechanical hypersensitivity, the combination of 
sleep fragmentation and musculoskeletal sensitization had dramatic and long-
lasting effects on subsequent sleep-wake behavior (Figures 9, 10).  Before any 
manipulations, mice used in group 3 exhibited normal diurnal distributions of 
sleep-wake behavior during baseline recording periods, with increased time 
spent in NREM and REM sleep during the light period and increased time spent 
in wakefulness during the dark period (data not shown).  To examine the impact 
of experimental manipulations, data obtained from mice among treatment groups 
were normalized to the pre-injection baseline measurements for the 12h light and 
dark periods and are expressed as the percent change from baseline ([post-
manipulation value / baseline value] x 100).  Because von Frey testing is 
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disruptive to spontaneous sleep and occurred early in the light period of post-
sensitization days 1, 3, 7, 14, and 21, sleep-wake behavior was determined from 
recordings that were obtained on post-sensitization days 2, 8, 15, and 22 from 
undisturbed mice. 
Following sleep fragmentation combined with musculoskeletal 
sensitization, sensitized mice had a significant increase in sleep-wake state 
transitions.  Increased sleep-wake state transitions were apparent during the light 
and during the dark periods, and differed statistically from pre-injection baseline 
values and from control mice injected with normal saline (Figure 9A,B).  These 
effects were robust, and persisted for the duration of the 22 day post-
sensitization period evaluated in this study. 
NREM sleep and wakefulness were altered during the post-manipulation 
period in mice that had been subjected to sleep fragmentation during 
musculoskeletal sensitization (acidified saline injections; Figure 10). The amount 
of time spent in REM sleep during the post-manipulation period did not differ 
among conditions, although there was a trend towards increased REM sleep 
during the light period on post-sensitization day 2 (Figure 10A). The combination 
of sleep fragmentation and musculoskeletal sensitization had differential effects 
on NREM sleep of mice during the post-manipulation period.  NREM sleep of 
sensitized mice was reduced during the light period across all recording days 
evaluated, and increased during the dark period on post-manipulation days 15 
and 22 (Figure 10B).  By comparison, mice injected with normal saline and 
subjected to sleep fragmentation had a modest increase in NREM sleep that was 
58 
 
restricted to the dark period of post-manipulation day 2 (Figure 10B).  
Wakefulness was significantly increased in sensitized mice during the light period 
on all post-manipulation recording days (Figure 10C).  Sensitized mice also had 
a significant decrease in wakefulness during the dark period on post-
manipulation days 15 and 22.  There were no significant changes in REM sleep 
or wakefulness of mice injected with normal saline (Figure 10A,C). 
Because of inter-animal variations in properties of the recorded EEG, 
analyses of NREM delta power were performed on values normalized to the 24-
hour average for each animal ([hourly value / 24 hour average] x 100)(23).  
These values were then expressed as the percent change from baseline ([post-
sensitization 12h normalized value / baseline 12h normalized value] x 100).  The 
combination of sleep fragmentation and musculoskeletal sensitization increased 
NREM delta power during the light period and decreased NREM delta power 
during the dark period.  These effects were most apparent on post-manipulation 
days 8, 15, and 22 (Figure 10D).  There were no changes in NREM delta power 
of mice injected with normal saline during the musculoskeletal sensitization 
period. 
Sleep fragmentation combined with musculoskeletal sensitization did not 
significantly alter daily food consumption, water consumption, or body weight.  
Repeated-measures ANOVA did not reveal a significant group or time effect on 




Results of this study demonstrate that disrupting sleep of mice during the 
light periods of the inter-injection interval required to induce musculoskeletal 
sensitization exacerbates mechanical hypersensitivity and alters subsequent 
sleep-wake behavior.  The combined effects of sleep fragmentation and 
musculoskeletal sensitization on sleep-wake behavior include increases in the 
number of sleep-wake state transitions, alterations in NREM sleep and 
wakefulness, and in delta power during NREM sleep.  Our data suggest that 
exacerbated mechanical hypersensitivity and changes in sleep-wake behavior 
under the conditions of this study are the result of a synergistic effect of sleep 
fragmentation combined with musculoskeletal sensitization.  Importantly, these 
data also demonstrate that in this pre-clinical model, sleep fragmentation 
exacerbates pain as manifest by prolonged induction of mechanical 
hypersensitivity.  
Data from this study demonstrate that sleep fragmentation combined with 
musculoskeletal sensitization increases the number of sleep-wake state 
transitions of mice during the light and dark periods for at least three weeks 
following sensitization.  We previously demonstrated that musculoskeletal 
sensitization by itself increases state transitions of sensitized mice during the 
light period, but not the dark period(116).  Increased numbers of state changes 
reflect poor sleep quality, and have been reported in several pre-clinical pain 
studies, including those of neuropathic and arthritic pain(161, 165, 199).  
Collectively, results of our previously published study(116) and these new data 
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suggest that sleep fragmentation combined with musculoskeletal sensitization 
exacerbates effects on sleep quality relative to responses to either manipulation 
alone.  These pre-clinical results contribute to a growing literature demonstrating 
that musculoskeletal sensitization fragments sleep.  Clinically, fibromyalgia is a 
chronic pain condition of unknown etiology that is characterized by fragmented 
sleep and musculoskeletal pain(221, 222).  Sodium oxybate, a medication that 
consolidates sleep, improves subjective pain ratings in fibromyalgia patients(241, 
242).  Consolidation of sleep may improve pain symptoms, especially in patients 
with ongoing musculoskeletal pain(175).  Additional studies are necessary to 
determine if sleep consolidation in this pre-clinical model would ameliorate pain 
symptoms associated with musculoskeletal sensitization.   
Musculoskeletal sensitization by itself, i.e., without concurrent sleep 
fragmentation, does not alter the amount of time mice spend in NREM sleep, 
REM sleep or wakefulness, or change delta power during NREM sleep(116).  A 
novel finding of this study is that when sleep fragmentation is combined with 
musculoskeletal sensitization, each of these parameters is altered.  Furthermore, 
these effects are prolonged, and persist for at least three weeks.  NREM sleep of 
mice subjected to sleep fragmentation combined with musculoskeletal 
sensitization is increased during the dark period and reduced during the light 
period (this study).  Reductions in NREM sleep are reported in other pre-clinical 
pain models, including nerve constriction injury(161, 166), osteoarthritis(199) and 
nerve ligation(200).  In our present study, changes in NREM sleep are mirrored 
by increased wakefulness during the light period and reduced wakefulness 
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during the dark period.  These changes in NREM sleep and wakefulness suggest 
insufficient sleep during the light period, which is compensated by a NREM sleep 
rebound during the dark period.  However, delta power during NREM sleep is 
increased during the light period and reduced during the dark period.  Although 
NREM sleep duration and delta power during NREM sleep may change in 
parallel, there is ample literature demonstrating dissociation between these two 
parameters under a variety of conditions [reviewed(24)].  Our data demonstrate 
that in this model of musculoskeletal sensitization not only are changes in NREM 
sleep duration and delta power during NREM sleep dissociated, but that the 
relationship between NREM sleep duration and delta power during NREM sleep 
is very complex.  Ample literature demonstrates that NREM delta power 
generally increases with duration of prior wakefulness [reviewed(24)].  Therefore, 
increased NREM delta power during the dark period is one anticipated 
consequence of insufficient sleep during the light period.  This is not the case for 
data obtained from mice in this study subjected to sleep fragmentation during the 
musculoskeletal sensitization period.  The precise mechanisms underlying the 
reciprocal changes in NREM sleep and delta power during NREM sleep in this 
model remain to be elucidated. 
REM sleep deprivation of humans or rodents enhances pain across 
sensory modalities including thermal, mechanical, chemical and electrical 
stimuli(176, 181, 183).  Conversely, REM sleep is reduced in animals subjected 
to some pre-clinical pain models, such as gouty arthritis(163), diabetic 
neuropathy(243), or orofacial pain(218).  Observations such as these suggest a 
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link between REM sleep and pain symptoms such that reduced REM sleep 
enhances pain, and/or enhanced pain reduces REM sleep.  Data obtained in this 
study demonstrate that sleep fragmentation by itself, i.e., in the absence of 
musculoskeletal sensitization, does not induce mechanical hypersensitivity.  
Although our sleep fragmentation method does not dramatically alter NREM 
sleep, REM sleep is essentially abolished during periods when the disc is 
rotating(65).  Our finding that sleep fragmentation by this method does not induce 
mechanical hypersensitivity may be important as studies of humans and rodents 
that use total sleep deprivation(177, 238), REM sleep deprivation(171, 180, 183), 
or sleep disruption(244, 245) report increases in pain symptoms using other 
outcome measures.  Ongoing studies aim to understand the impact of sleep 
disruption by this method on multiple aspects of rodent physiology and behavior, 
including pain symptoms.  This initial study using this method and protocol to 
disrupt sleep of mice suggests that five days of REM sleep loss during the light 
period may not have the same impact on pain symptoms in otherwise healthy 
rodents as reported in some studies that used other approaches to eliminate or 
disrupt sleep, or in other pain models.     
Musculoskeletal sensitization does not damage peripheral tissue, and 
mechanical hypersensitivity in this model is mediated by changes in the central 
nervous system(110, 118).  Sleep fragmentation combined with musculoskeletal 
sensitization enhances mechanical hypersensitivity to a greater extent than that 
elicited by musculoskeletal sensitization alone, i.e., there is an exacerbated 
response.  Our data indicate that the combination of sleep fragmentation and 
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musculoskeletal sensitization induces mechanical hypersensitivity at least two 
days earlier than when musculoskeletal sensitization occurs in mice allowed 
undisturbed sleep.  In addition, the exacerbated mechanical hypersensitivity is 
apparent 21 days after sensitization.  One possible explanation for the 
exacerbated increase in mechanical hypersensitivity three weeks after 
sensitization is the change in sleep that occurs during this period.  In human 
subjects, sleepiness increases subjective pain and lowers thresholds for evoked 
pain responses(192, 193).  Three weeks after sensitization, sleep-wake behavior 
of mice during the light period is altered such that NREM sleep duration is 
reduced, there is more wakefulness, and the number of sleep-wake state 
transitions is increased.  These changes in sleep of mice indicate sleep of poor 
quality that fundamentally differs from sleep during baseline conditions prior to 
musculoskeletal sensitization.  Although the manipulations used in this study 
induce complex changes in NREM delta power and NREM sleep duration, these 
data suggest that in mice the quality of sleep contributes to pain perception.  
Within this context, musculoskeletal sensitization combined with sleep 
fragmentation may model aspects of the relationship between sleep and pain 
reported in human subjects(7, 17, 55).   
Sleep deprivation, disruption, and fragmentation can all contribute to a 
systemic proinflammatory state(63, 246, 247).  Circulating proinflammatory 
cytokines increase under conditions of disrupted sleep in rodents and human 
subjects(247-249).  Sleep fragmentation may thus contribute to an inflammatory 
state that alters outcomes of musculoskeletal sensitization.  Unpublished data 
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from our laboratory demonstrate that sleep fragmentation of mice during the light 
period by the method used in this study increases proinflammatory cytokines in 
plasma and discrete brain regions.  Sleep fragmentation by this method also 
enhances the febrile response of mice to an intraperitoneal lipopolysaccharide 
(LPS) injection(65).  Lipopolysaccharide, an endotoxin found in the membrane of 
gram-negative bacteria, induces a systemic inflammatory response.  
Musculoskeletal sensitization can be induced by replacing the first intramuscular 
injection of acidified saline with a systemic injection of LPS, suggesting 
inflammation is a critical component of musculoskeletal sensitization(250).   An 
LPS injection into rats that precedes intramuscular injection of acidified saline by 
5 days is sufficient to induce mechanical hypersensitivity that is similar in 
magnitude to that of animals subjected to 2 intramuscular injections of acidified 
saline(250).  Ongoing studies in our laboratory focus on the role of inflammatory 
mediators in this model of sleep fragmentation combined with musculoskeletal 
sensitization.  
Bi-directional relationships among multiple facets of sleep and pain exist 
such that pain disrupts sleep and insufficient sleep contributes to pain.  The bi-
directional relationships between sleep and pain may be important clinically.  
Sleep restriction to three and a half hours of sleep per night for a week in healthy 
volunteers produces pain sensitivity comparable to that of patients suffering from 
chronic pain conditions(172).  After a period of recovery sleep, pain measures 
from these subjects return to normal(172).  Healthy subjects who report sleeping 
more than 9h or less than 6h per night have greater next-day pain scores(174).  
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Increasing the sleep opportunity of healthy individuals by 2h a night for 4 nights 
significantly raises pain thresholds to a radiant heat stimulus(193).  Sleepiness 
also impacts the efficacy of common treatments for pain.  Patients given a sleep 
aid as part of post-surgical care have less subjective pain and require fewer 
analgesic doses to control pain than patients without a sleep aid(251, 252).  
Sleep deprived rats are resistant to the effects of opioid drugs that enhance 
tolerance to noxious stimuli, and do not receive the same analgesic benefits from 
these agents as well-rested rats(253, 254).  The decreased efficacy of opioids in 
sleep-deprived rats may be clinically important given the widespread use of these 
agents to treat musculoskeletal pain(101, 255). Patients with chronic 
musculoskeletal pain often have poor sleep quality(102, 256).  Pre-clinical data 
suggest that poor sleep quality, in turn, impacts the effectiveness of opioids in 
reducing pain.  Conversely, acute opioid administration negatively impacts sleep 
quality in humans(257).  Chronic administration of opioids has deleterious effects 
on sleep and contributes to the development of disordered breathing that can 
fragment sleep(101, 258).  Collectively, these data raise the possibility that 
musculoskeletal pain fragments sleep, which could further enhance pain and 
make patients resistant to opioid treatment contributing to an even further 
deterioration in sleep quality.  This complex interrelationship among sleep, pain 
and opioids, a drug class commonly prescribed for the treatment of pain, further 
underscores the need for research focused on insufficient sleep, chronic pain, 
and analgesic administration. 
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In conclusion, our data demonstrate that in this model, sleep 
fragmentation combined with musculoskeletal sensitization induces prolonged 
effects on mechanical hypersensitivity and sleep-wake behavior of mice.  These 
effects result from synergistic interactions between sleep fragmentation and 
musculoskeletal sensitization, and do not result from sleep fragmentation or from 
musculoskeletal sensitization per se.  Given the prevalence and increasing 
incidence of insufficient sleep in the United States, the relationship between 
chronic pain and sleep will continue to be a prominent public health issue.  
Additional pre-clinical, translational, and clinical investigations are needed so that 














Figure 4. Experimental protocol to determine the impact of sleep 
fragmentation in combination with musculoskeletal sensitization on 
mechanical hypersensitivity and subsequent sleep-wake behavior of mice   
Mice in group 3 (n=22) were used to determine the impact of sleep fragmentation 
combined with musculoskeletal sensitization on mechanical hypersensitivity.  
These mice were subjected to sleep fragmentation during the 5 day interval 
between the first and second intramuscular injections.  A subset of mice (n=16) 
was used to determine the impact of sleep fragmentation combined with 
musculoskeletal sensitization on subsequent sleep-wake behavior.  These n=16 
mice were implanted with telemeters, and allowed 3 weeks of recovery.  Baseline 
EEG and body temperature recordings were then obtained for two days.  All mice 
(instrumented, uninstrumented) were habituated to the von Frey testing 
procedures, which was then followed by one day of habituation to the sleep 
disruption device.  Mice then were randomized into an acidified or normal saline 
injection group (n=11 per injection; n=8 with telemeters per injection group).  The 
first injection with acidified or normal saline was given at light onset, which was 
followed by sleep fragmentation for 5 consecutive light periods before the second 
injection was given.  Testing with von Frey filaments took place on post-
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Figure 5. Sleep fragmentation by itself does not induce mechanical 
hypersensitivity 
Mice in group 1 (n=12) that had sleep fragmented for 5 consecutive light periods 
(days) did not develop mechanical hypersensitivity.  Response incidence to von 
Frey filament presentation did differ among baseline (BL), sleep fragmentation 
day 3 (SF3), or post-fragmentation days 1, 3, and 7 in either the left or right 
hindpaw.  Responses to von Frey filaments are plotted as mean ± SEM percent 
of total response incidence ([total responses / total filament presentations] x 100) 




































Figure 6. Musculoskeletal sensitization induces bilateral mechanical 
hypersensitivity 
Mechanical hypersensitivity in mice was induced by two injections of acidified 
saline spaced 5 days apart.  Mechanical hypersensitivity manifested as 
increased response incidence to von Frey filaments on post-sensitization days 3 
through 21.  Mechanical hypersensitivity developed to the same extent in the 
hindpaw contralateral to the leg that contained the intramuscular injection site.  
Responses to von Frey filaments are plotted as mean ± SEM percent of total 
response incidence ([total responses / total filament presentations] x 100) per 
paw from n=24 mice (n=12 acidified saline, n=12 normal saline). *, p < 0.05 vs. 
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Figure 7. Sleep fragmentation combined with musculoskeletal sensitization 
induces bilateral mechanical hypersensitivity 
Mice in which sleep was fragmented during the musculoskeletal sensitization 
period developed mechanical hypersensitivity that lasted for at least 21 days.  .  
Mechanical hypersensitivity developed to the same extent in the hindpaw 
contralateral to the leg that contained the intramuscular injection site.  
Responses to von Frey filaments are plotted as mean ± SEM percent of total 
response incidence ([total responses / total filament presentations] x 100) per 
paw from n=22 mice (n=11 acidified saline, n=11 normal saline; n=8 mice in each 
injection group had implanted telemeters).  BL = baseline; SF = sleep 
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Figure 8. Sleep fragmentation combined with musculoskeletal sensitization 
exacerbates mechanical hypersensitivity 
Comparisons were made between mice allowed undisturbed sleep during the 
musculoskeletal sensitization period (group 2) and mice in which sleep was 
fragmented during the sensitization period (group 3).  Response incidence values 
did not differ among manipulation groups at baseline (BL).  Mechanical 
hypersensitivity did not develop in mice injected with normal saline, irrespective 
of whether or not sleep was undisturbed or fragmented.  Mice subjected to sleep 
fragmentation during the musculoskeletal sensitization period exhibited greater 
mechanical hypersensitivity on the day 1 and day 21 post-sensitization than did 
mice that were sensitized without sleep fragmentation.  Responses to von Frey 
filaments are plotted as mean ± SEM percent of total response incidence ([total 
responses / total filament presentations] x 100) per paw for the leg ipsilateral to 
the injection site. +, p < 0.05 vs. undisturbed sleep + acidified saline. *, p < 0.05 
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Figure 9. The combination of sleep fragmentation and musculoskeletal 
sensitization disrupts subsequent sleep for prolonged periods 
(A) The average number of sleep-wake state transitions per hour across the 24h 
light:dark period is plotted for pre-injection baseline and post-manipulation days 
2, 8, 15, and 22.  All mice were subjected to sleep fragmentation (SF) with or 
without musculoskeletal sensitization (acidified saline, normal saline injections).  
Sleep fragmentation combined with musculoskeletal sensitization significantly 
increased state transitions per hour during the light and during the dark periods.  
(B) The percent change from baseline (BL) for the 12h light and the 12h dark 
period is plotted for post-sensitization days 2, 8, 15, and 22.  On all post-
manipulation days, mice with musculoskeletal sensitization (acidified saline) had 
significantly more sleep-wake state transitions than mice without musculoskeletal 
sensitization (normal saline), an effect apparent during the light period and during 
the dark periods.  Values are the mean ± SEM for n=7 mice per injection group.  
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Figure 10. The combination of sleep fragmentation and musculoskeletal 
sensitization alters duration and quality of subsequent sleep 
The impact of sleep fragmentation (SF) during the musculoskeletal sensitization 
period on rapid eye movements (REM) sleep, non-REM (NREM) sleep, 
wakefulness, and delta power during NREM sleep is presented as percent 
change from baseline (BL) values.  Values are the mean ± SEM for n=7 mice per 
injection group.  (A) Although there was a trend for increased REM sleep on the 
second post-sensitization day, this deviation did not achieve statistical 
significance (light period p = 0.716; dark period p = 0.556).  REM sleep was not 
altered after sleep fragmentation combined with musculoskeletal sensitization. 
(B) NREM sleep of mice subjected to the combination of sleep fragmentation and 
musculoskeletal sensitization was decreased during the light period across all 
post-manipulation days, and increased during the dark period on post-
manipulation days 15 and 22.  (C) Wakefulness during the light period of mice in 
which sleep fragmentation was combined with musculoskeletal sensitization 
increased during the entire post-sensitization period.  Sensitized mice had 
significantly less wakefulness during the dark period on post-manipulation days 
15 and 22. (D) NREM delta power in mice subjected to sleep fragmentation and 
musculoskeletal sensitization significantly increased during light periods and 
decreased during dark periods.  For all panels, #, p < 0.05 vs. pre-manipulation 




INTRAMUSCULAR INFLAMMATORY CYTOKINES ARE 
NECESSARY FOR THE DEVELOPMENT OF MECHANICAL 
HYPERSENSITIVITY IN A MOUSE MODEL OF 
MUSCULOSKELETAL SENSITIZATION 
ABSTRACT 
Musculoskeletal pain is a widespread health problem in the United States, 
with back pain, neck pain, and facial pain constituting three of the most prevalent 
types of chronic pain. Cytokines contribute to pain during a variety of pathologies.  
Despite its prevalence in the United States, preclinical research investigating 
musculoskeletal pain is limited.  Musculoskeletal sensitization is a preclinical 
model of muscle pain that produces mechanical hypersensitivity.  In a rodent 
model of musculoskeletal sensitization, mechanical hypersensitivity develops at 
the hindpaws after injection of acidified saline (pH 4.0) into the gastrocnemius.  In 
this study, we investigate the role of intramuscular cytokines in the development 
of mechanical hypersensitivity after musculoskeletal sensitization.  Intramuscular 
concentrations of interleukin-1 (IL-1), IL-6 and tumor necrosis factor- (TNF) 
were quantified following injection of normal (pH 7.2) or acidified saline into the 
gastrocnemius muscle.  A cell-permeable NF-κB inhibitor was used to determine 
the impact on mechanical hypersensitivity of inhibiting nuclear translocation of 
NF-κB prior to musculoskeletal sensitization.  The role of individual cytokines in 
mechanical hypersensitivity following musculoskeletal sensitization was 
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assessed using knockout mice lacking components of the IL-1, IL-6 or TNF 
systems.  Collectively, our data demonstrate that acidified saline injection 
increases intramuscular IL-1 and IL-6, but not TNF; that intramuscular pre-
treatment with an NF-κB inhibitor blocks mechanical hypersensitivity; and that 
genetic manipulation of the IL-1 and IL-6, but not TNF systems, prevents 
mechanical hypersensitivity following musculoskeletal sensitization.  These data 
establish that actions of IL-1 and IL-6 in local muscle tissue play an acute 
regulatory role in the development of mechanical hypersensitivity following 
musculoskeletal sensitization. 
INTRODUCTION 
Chronic pain is a significant health problem in the United States and is 
associated with high personal and economic costs.  Chronic pain conditions 
involving musculoskeletal pain are particularly burdensome because low back 
pain, neck, and facial pain constitute three of the most prevalent chronic pain 
conditions in the United States(4).  Total annual costs associated with chronic 
pain are estimated upwards of $635 billion in the United States alone, including 
treatment costs and lost work productivity(5).  Pain is one of the leading causes 
of absenteeism from work and presents physical, social and psychological 
barriers to working(259).  Pain control for patients with musculoskeletal pain is 
poor and drug dependency can occur from opioid treatment(101).  These 
demographic and epidemiologic data underscore the need for understanding 
mechanisms by which chronic musculoskeletal pain develops.  Such knowledge 
may lead to new or more effective treatment interventions and thus improve 
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quality of life for patients and reduce overall costs associated with this public 
health burden. 
Data demonstrate that inflammatory cytokines are mediators and 
modulators of many pain conditions(260-262).  The inflammatory cytokines 
interleukin-1 (IL-1), IL-6, and tumor necrosis factor- (TNF) are all involved in 
muscle pain(134, 263).  Elevated inflammatory cytokines are detected in plasma 
and tissue biopsies of patients with chronic pathologies characterized by muscle 
pain(264-266).  Targeting inflammatory cytokines for inhibition is effective in 
relieving pain of patients with rheumatoid arthritis(267) and ankylosing 
spondylitis, a form of chronic inflammatory arthritis(268).  Inhibition of cytokines 
also relieves pain in pre-clinical models of neuropathic pain(137, 269), spinal 
nerve ligation pain(135), and experimental arthritis(270).  Mice lacking 
components of the IL-1, IL-6, or TNF systems through genetic knockout do not 
develop the same intensity of pain as genetically intact mice in models of gouty 
arthritis, chronic inflammation, and nerve transection(271-273).  
Reduced tissue pH is a characteristic of painful conditions induced by 
inflammation, muscle spasm, exhausting exercise, cancer, and ischemia, for 
example(274-277).  Intramuscular injection of acidified saline reduces local tissue 
pH by increasing extracellular hydrogen ion (H+) concentrations, and injection of 
acidified saline into the gastrocnemius muscle of rodents is used to study chronic 
muscle pain(114).  In this rodent model, musculoskeletal sensitization by 
injection of acidified saline produces long-lasting bilateral secondary mechanical 
hypersensitivity at the hind paws(115, 116, 278).  This rodent model of 
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musculoskeletal sensitization is clinically relevant, in part, because intramuscular 
injection of acidified saline into human volunteers produces muscle hyperalgesia 
and referred pain(279). 
In this study we focus on inflammatory cytokines as mediators of 
musculoskeletal sensitization-induced mechanical hypersensitivity.  Specifically, 
we hypothesize that IL-1, IL-6, and TNF are critical for the development of 
mechanical hypersensitivity following musculoskeletal sensitization.  To test this 
hypothesis, we quantified cytokine concentrations in the mouse gastrocnemius 
muscle after intramuscular injection with normal or acidified saline; we targeted 
transcription of these three cytokines by inhibiting nuclear translocation of NF-κB; 
and we used genetically modified mice lacking components of the IL-1, IL-6 or 
TNF systems to determine relative contributions of these cytokines to mechanical 
hypersensitivity after musculoskeletal sensitization.  We now report that IL-1 and 
IL-6, but not TNF, increase in muscle after intramuscular injection of acidified 
saline.  Local inhibition of nuclear translocation of NF-κB in the gastrocnemius 
muscle prior to musculoskeletal sensitization blocks the development of 
mechanical hypersensitivity; and genetic manipulation of the IL-1 and IL-6, but 
not TNF, systems prevents mechanical hypersensitivity following musculoskeletal 
sensitization.  Collectively, our new data demonstrate that intramuscular IL-1 and 
IL-6 are local mediators of the development of mechanical hypersensitivity 





Adult male mice (8-12 weeks; 25 g) were used in this study.  Mice were 
either purchased from the Jackson Laboratory (Bar Harbor, ME), or bred in-
house as detailed later.  All mice were maintained on a 12:12 h light:dark cycle at 
27 °C with ad libitum access to food and water.  Mice were group housed, and 
mice shipped from the Jackson Laboratory were allowed a minimum of one week 
to acclimate after arrival in our animal facility.  All procedures using mice in these 
studies were approved in advance by the University of Washington Institutional 
Animal Care and Use Committee (IACUC), in accordance with the US 
Department of Agriculture Animal Welfare Act and the National Institutes of 
Health policy on Humane Care and the Use of Laboratory Animals. 
Musculoskeletal Sensitization 
Acidified saline injections were used to produce long-lasting bilateral 
secondary mechanical hypersensitivity at the hindpaws(114-116).  Mice were 
briefly anesthetized using isoflurane and injected unilaterally into the 
gastrocnemius muscle with 20 uL of pyrogen-free saline using a 31g insulin 
syringe.  All mice were randomized into normal (pH 7.2) or acidified (pH 4.0) 
saline injection groups.  Saline was adjusted to acidified (pH 4.0) pH using 0.1M 
HCl or NaOH.  The leg into which injections were made was randomized among 
mice to prevent any lateralization bias.  All animals were immediately returned to 
their home cage after injections and observed by the investigator until fully 
ambulatory.  
Mechanical Hypersensitivity Testing 
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The von Frey filament test is used to measure sensitivity to a non-noxious 
punctate pressure stimulus.  All habituation and testing procedures took place at 
light onset and were completed during the first 2 hours of the light period.  Mice 
were habituated to a galvanized steel mesh testing platform for a minimum of 60 
minutes for 3 days prior to baseline testing.  During testing, mice were given a 
minimum of 30 minutes to habituate to the testing platform or until quiet.  
Calibrated filaments (0.07, 0.45, & 1.45 g) were presented in ascending order to 
the glaborous skin of the hindpaw until the filament bowed slightly for 3 
continuous seconds(116, 117).  Testing continued until all 3 filaments were 
presented 5 times per paw with a minimum of 1-minute break between filaments.  
If mice became too active, testing was suspended until they were quiet.  Positive 
responses were recorded when mice retracted the paw in response to the 
filament pressure.  Mice were tested on 3 baseline days and 1, 3, 7, 14, and 21 
days after the second sensitization injection. 
Experiment 1: Quantification of intramuscular cytokine concentrations after 
musculoskeletal sensitization 
A total of 62 mice were used for this experiment.  The gastrocnemius 
muscles ipsilateral and contralateral to the injection site were collected from all 
mice.  Four mice that were not injected were sacrificed at light onset to serve as 
un-injected controls.  Fifty-eight mice (n=29 per injection group) were injected 
intramuscularly at light onset with either 20 uL normal (pH 7.2) or acidified (pH 
4.0) saline.  Twenty-four mice (n=4 per time point per injection group) were 
sacrificed 60, 90, or 120 minutes after the first intramuscular injection (injection 
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1).  The remaining 34 mice were housed for 5 days without manipulation.  Five 
days later, 24 mice received a second injection of normal or acidified saline 
(injection 2).  Muscle tissues were collected from these animals 60, 90 or 120 
minutes after injection (n=4 per time point per injection group).  The remaining 
mice (n=10; 5 per injection group) were sacrificed at light onset without a second 
intramuscular injection and served as controls for the second intramuscular 
injection procedure.  All muscle tissues were rapidly dissected from the hind limb, 
skin removed, snap-frozen in liquid nitrogen, and stored at −80 °C until 
processing.  
Protein extractions: Frozen tissues were thawed and disrupted in Bioplex 
cell lysis buffer (BioRad catalog # 171-304011) containing protease and 
phosphatase inhibitors (BioRad catalog # 171-304012) and the protease inhibitor 
phenyl-methylsulfonyl fluoride (PMSF, 500 mM; Sigma–Aldrich).  Tissue was 
grossly dissected using surgical scissors, disrupted using a 1000 uL pipette with 
the tip cut off, and homogenized with a sonic dismembrator (Fisher, #FB-501-10).  
The homogenate was then agitated for 30–40 min on ice and centrifuged at 4 °C 
and 6000 × g for 20 min.  The supernatant was removed, aliquoted and stored at 
−80 °C until assay.  The protein content of each sample was determined using 
the bicinchoninic acid (BCA) assay (Pierce catalog # 23225, Rockford, IL), with 
bovine serum albumin (BSA) as a standard, according to the manufacturer's 
protocol. 
Determination of cytokine concentrations: Custom bead sets were created 
in-house for all assays. xMAP Antibody coupling kits (Product #40-50016, 
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Luminex Corportation, Austin, TX), capture antibodies from antibody specific duo 
sets for murine IL-1, IL-6, and TNF (DY401E; DY406E; DY410E respectively; R 
& D Systems) and MagPlex microspheres for coupling (MC10034-YY, MC10038-
YY, MC10065-YY; Luminex) were purchased.  Beads were coupled to antibodies 
at a concentration of 5 ug of capture antibody per million beads.  Briefly, reagents 
were brought to room temperature and beads were resuspended, pipetted into a 
reaction tube, and washed.  Activation buffer was added, and the beads were 
rewashed.  Sulfo-NHS, EDC, and activation buffer was added to the reaction 
tube and allowed to incubate for 20 minutes at 15-30 rpm on an orbital shaker.  
The microspheres were then washed a second time, activation buffer added 
again, then the appropriate capture antibody was added to the reaction tube and 
incubated for 2 hours at 15-30 rpm.  Lastly, the beads were washed and stored 
at 4 °C protected from light until use. 
All protein samples were run in duplicate in multiplexed assays.  A total of 
100 ug of muscle protein, as determined by the BCA assay, was loaded per well, 
and the volume brought to 50 ul per well using PBS with 1% BSA.  Duo set 
recombinant standards for murine IL-1, IL-6, and TNF were serially diluted to 
create a 7-point standard curve. The concentration ranges for the standard 
curves were 27–20,000 pg/ml for each of the three cytokines. 
The assays were run using a protocol similar to that used with 
commercially-available Bio-Plex kits. General practices included warming all 
reagents to room temperature prior to use, minimizing exposure of the beads to 
light by wrapping tubes and/or plates with aluminum foil, and using appropriate 
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agitation on a microplate shaker (600 rpm).  Samples were incubated with the 
beads overnight at 4 °C.  After warming to room temperature, a magnetic 
separator (Part #CN-0269-01, Luminex) was used to separate beads from the 
supernatant.  Beads were washed and then incubated with detection antibodies 
(R&D Systems) for 30 minutes.  After washing, the beads were incubated with 
phycoerythrin (#S866, Invitrogen) for 30 minutes and then washed a final time 
prior to analysis.  The plates were read with a Bio-Plex 200 System, and the data 
analyzed using BioPlex Manager 4.1 software with five-parameter logistic 
regression (5PL) curve fitting.  The goodness-of-fit for each point on the standard 
curve was determined by the BioPlex Manager software as a back-calculation of 
standards.  
Experiment 2: Effects on mechanical sensitivity of intramuscular inhibition 
of NF-κB prior to musculoskeletal sensitization 
A commercially available, cell-permeable peptide (SN50; EMD Millipore) 
was used to determine the impact of inhibition of nuclear translocation of NF-kB 
during musculoskeletal sensitization on mechanical sensitivity.  Forty mice were 
randomized into control peptide (SM50; EMD Millipore) or inhibitor peptide 
groups and further randomized into a normal or acidified pH saline injection 
group.  This randomization process yielded 4 manipulation groups (n=10 per 
group): control peptide + normal pH saline, control peptide + acidified pH saline, 
inhibitor peptide + normal pH saline, and inhibitor peptide + acidified pH saline.  
Prior to manipulation all mice were habituated to the von Frey testing platform 
and baseline values for mechanical hypersensitivity were obtained as described 
85 
 
earlier.   After habituation and baseline von Frey testing, mice were randomized 
and injected intramuscularly at light onset with either the NF-κB inhibitor peptide 
or control peptide at a dose of 200 ng / 10 ul in saline.  One hour later, the same 
muscle was injected with either normal (pH 7.2) or acidified (pH 4.0) saline per 
the randomization protocol (injection 1).  The exact same procedure was 
repeated 5 days later (injection 2), with each mouse receiving the same 
substances as given for injection 1.  Mechanical hypersensitivity was assessed 
on post-sensitization days 1, 3, 7, 14, and 21 using von Frey testing as 
described.   
Experiment 3: The impact of genetic knockout of IL-1 receptor 1 (IL1R1), 
IL-6, or TNF receptor 1 (TNFR1) on musculoskeletal sensitization-induced 
mechanical sensitivity 
Mice for this experiment were either purchased or bred in-house.  
C57BL/6J and B6.129S6-II6tm1Kopf (IL-6 knockout [IL-6 KO]) mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME).  IL-6 KO mice were originally 
generated on a 129S6 background(280), but have been backcrossed onto a 
C57BL/6J background for more than 11 generations.  We have previously used 
these IL-6 KO mice in studies of responses to immune challenge(204, 281, 282).  
Three strains generated in-house were used:  Il1r1-/- (IL-1R1 KO), Tnfr1-/- 
(TNFR1 KO), and wild type control (Il1r1+/+ Tnfr1+/+; WT).  Mice with Il1r1 targeted 
null allele and Tnfr1 targeted null allele were acquired from the Jackson 
Laboratory as a double knockout strain B6;129S-Tnfrsf1atm1Imx Il1r1tm1Imx/J (stock 
#003244).  To have mutant and wild type control strains on the same genetic 
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background, we generated WT mice by crossing homozygous null Il1r1-/- with 
homozygous null Tnfr1-/- animals and then intercrossing their progeny.  All three 
strains are on mixed genetic background (C57BL/6, 129S1/SvImJ, and SJL with 
about 50% C57BL/6).  All mice bred in-house were genotyped prior to use in 
experiments. 
Twenty mice per genetic strain were used for this experiment (n=100 
total).  Experiments began when mice were between 8-12 weeks old.  All mice 
were habituated to the von Frey testing platform, and baseline mechanical 
hypersensitivity values using von Frey filaments were obtained as described 
above.  After baseline von Frey testing, mice were randomized into either normal 
(pH 7.2) or acidified (pH 4.0) saline injection groups (n=10 mice per injection 
group per genotype), and two intramuscular injections were administered 5 days 
apart, as in Experiments 1 and 2.  Following the second injection, mechanical 
hypersensitivity was assessed on days 1, 3, 7, 14, and 21. 
Statistical Analysis 
Statistical analyses were performed using SPSS for Windows.  All data 
are presented as mean ± standard error of the mean (SEM).  Cytokine protein 
concentrations obtained in Experiment 1 were analyzed using a one-way ANOVA 
with manipulation (acidified saline, normal saline) as the fixed effect and protein 
(IL-1, IL-6, TNF) as the random effect. The Bonferroni correction was used for 
multiple comparisons to determine changes in cytokine protein across time. 
However, cytokine values were only analyzed for those time-points at which 
values were above the lower limit of detection (~27 pg/mL) of the custom bead 
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sets used in this study (see Methods Section). A p value ≤ 0.05 was accepted as 
indicating statistical significance for all analyses. 
To determine if there was an effect of intramuscular injections, NF-kB 
inhibition or genetic manipulation of selected cytokine systems on mechanical 
sensitivity, comparisons were made by evaluating total response incidence ([total 
number of responses per paw / 15 possible responses per paw] x100) for the 
paw ipsilateral and contralateral to intramuscular injection.  Repeated-measures 
ANOVA with the between-subjects factor of treatment or genotype and a within-
subjects factor of time (post-sensitization day of the experimental protocol) was 
used to statistically evaluate response incidence values from ipsilateral and 
contralateral paws. A p value ≤ 0.05 was accepted for all statistical tests as 
indicating significant departures between the groups across the testing period. 
RESULTS 
Experiment 1: Quantification of intramuscular cytokine concentrations after 
musculoskeletal sensitization 
Cytokine protein concentrations were below the limit of detection in all 
tissue samples taken from mice injected with normal pH saline and in all samples 
from the muscle contralateral to the injection site, irrespective of time point and/or 
treatment group (data not shown).  Because cytokine concentrations in all control 
samples (no injection or injection with normal pH saline) were below the limit of 
detection, an arbitrary value of 0.5 pg/ml was assigned to these samples to allow 
statistical comparisons to be made.  All samples were run twice on plates 
containing mixed sample conditions.  IL-1 was significantly elevated across time 
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points after the first injection [F(3,16) = 35542.959, p < 0.01] and after the second 
injection [F(3,14) = 20915.095, p < 0.01] (Fig. 11A).  IL-6 was significantly 
elevated in samples taken after the first injection [F(3,11) = 1721.481, p < 0.01], 
but samples taken after the second injection were all below the lower limit of 
detection (Fig. 11B). IL-6 is released from muscle tissue during stimulation, 
especially exercise, however the release of IL-6 rapidly adapts to repeated 
stimuli(97, 283). TNF was below the limit of detection in all samples (data not 
shown). 
Experiment 2: Effects on mechanical sensitivity of intramuscular inhibition 
of NF-κB prior to musculoskeletal sensitization 
Pre-injection baseline values obtained by von Frey testing indicated that 
mechanical sensitivity did not differ among mice subsequently randomized into 
one of the four injection groups (Fig. 12; [F(3,86) = 0.228, p = 0.877]).  Repeated 
measures ANOVA revealed a significant effect of injection group on response 
incidence [F(1,3) = 97.028, p < 0.01], and post-hoc analysis identified the 
average response incidence of the control peptide + acidified saline injection 
group (42.8 +/- 1.3 %) as differing significantly from the other 3 injection groups 
(control peptide + normal saline, 15.5 +/- 1.3 %; inhibitor peptide + normal saline, 
16.7 +/- 1.1 %; inhibitor peptide + acidified saline, 20.7 +/- 1.1 %) across the 3-
week post-injection period (Fig. 12).   
Experiment 3: The impact of genetic knockout of IL-1R1, IL-6, or TNFR1 
on musculoskeletal sensitization-induced mechanical sensitivity 
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Response incidence did not differ between ipsilateral and contralateral 
sides irrespective of genotype or injection group (data not shown).  Therefore, for 
ease of visual presentation only data from the leg ipsilateral to the injection site 
are presented.  Similarly, pre-injection baseline response incidence values did 
not differ significantly among genotypes or injection groups.   
IL1R1 KO mice:  Mice lacking IL1R1 did not develop mechanical 
hypersensitivity after musculoskeletal sensitization.  Repeated measures ANOVA 
revealed a significant effect of injection (normal pH vs. acidified pH; [F(1,34) = 
27.679, p < 0.01]) and genotype (IL1R1 KO vs. WT; [F(1,34) = 31.906, p < 0.01] 
on response incidence across the 21 day post-sensitization testing period (Fig. 
13A).  WT mice in which musculoskeletal sensitization had been induced by 
injections of acidified saline developed mechanical hypersensitivity manifest by 
increased response incidence to von Frey filaments.  There was a significant 
injection x genotype interaction on response incidence, indicating that IL-1R1 KO 
mice injected with acidified saline did not develop mechanical hypersensitivity 
(Fig. 13A; [F(1,34) = 20.663, p < 0.01]).   
IL-6 KO mice:  IL-6 KO mice did not develop mechanical hypersensitivity 
after musculoskeletal sensitization (Fig. 13B).  Repeated measures ANOVA 
revealed a significant effect of injection on response incidence (normal pH vs. 
acidified pH; [F(1,46) = 26.304, p < 0.01]) across the 21 day post-sensitization 
period.  There was a significant effect of genotype on response incidence 
(C57BL/6J vs. IL-6 KO; [F(1,46) = 66.950, p < 0.01]), and a genotype x injection 
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interaction demonstrating that IL-6 KO mice did not develop mechanical 
hypersensitivity following acidified saline injection [F(1,46) = 11.113, p < 0.05].   
TNFR1 KO mice:  Mice lacking TNFR1 developed mechanical 
hypersensitivity after musculoskeletal sensitization to the same extent as did WT 
mice (Fig. 13C).  Repeated measures ANOVA revealed a significant effect of 
injection on response incidence across the 21 day post-sensitization period 
(normal pH vs. acidified pH; [F(1,34) = 87.459, p < 0.01]).  There was no effect of 
genotype on response incidence (WT vs. TNFR1 KO; [F(1,34) = 0.278, p = 
0.601]). 
DISCUSSION 
Results of these experiments provide data demonstrating that IL-1 and IL-
6 play a critical role in the development of mechanical hypersensitivity after 
musculoskeletal sensitization.  Injection with acidified saline causes an 
intramuscular increase of IL-1 and IL-6, and intramuscular inhibition of nuclear 
translocation NF-κB prevents mechanical hypersensitivity after musculoskeletal 
sensitization.  Furthermore, genetic modification such that components of the IL-
1 or IL-6 systems are lacking completely eliminates the development of 
mechanical hypersensitivity in this mouse model of musculoskeletal sensitization. 
NF-κB is a transcription factor that regulates the expression of hundreds of 
genes(284) and is expressed ubiquitously in cells, including skeletal 
muscle(285).  NF-κB, in part, regulates gene transcription of the inflammatory 
cytokines IL-1, IL-6 and TNF(284), making it a target for inhibition of transcription 
for all three cytokines.  Our new data demonstrate that inhibiting nuclear 
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translocation of NF-κB locally in the muscle prevents the mechanical 
hypersensitivity that follows acidified saline injections.  Inhibiting nuclear 
translocation of NF-κB also blocks pain in other pre-clinical models including 
corneal burn(286), trigeminal neuropathy(287), HIV induced inflammation(288), 
and post-ischemia pain(289, 290).  Painful skeletal muscle disorders including 
Duchenne’s muscular dystrophy are associated with increased NF-κB activity in 
humans(291).  Duchenne’s is also modeled pre-clinically using a genetic mouse 
model that has increased NF-κB activity and produces muscle pain(292). Our 
data contribute to the literature demonstrating a role of NF-κB in the regulation of 
chronic pain, and extend existing data by indicating that in this model local 
actions of NF-κB are critical to the development of musculoskeletal sensitization. 
IL-1 and IL-6 increase in muscle tissue after injection of acidified saline, 
and knockout mice lacking IL-1R1 or IL-6 do not develop mechanical 
hypersensitivity after musculoskeletal sensitization.  IL-6 is synthesized and 
released directly from skeletal muscle and is considered to be a myokine, or 
cytokine released from muscle that can contribute to pain(97).  IL-1 increases 
intramuscular expression of acid sensing ion channels (see later).  Extracellular 
acidosis increases the production of IL-1 in monocytes through the stimulation of 
pro-IL-1 mRNA synthesis, the precursor to IL-1(293).  Our data clearly 
demonstrate a role for IL-1 and IL-6 as mediators of mechanical hypersensitivity 
in this model.  It is possible based on in vitro studies demonstrating the selective 
release of IL-1 from monocytes and IL-6 from myocytes that the IL-1 and IL-6 
detected during musculoskeletal sensitization is produced from different cell 
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types.  In, contrast, TNF along with IL-1 were two of the first cytokines identified 
as enhancing nociception(294, 295) and there is ample literature supporting the 
role of TNF in other pain models(128, 296).  However, our data also demonstrate 
that TNF does not play a role in this model: injection of acidified saline does not 
increase TNF in muscle tissue, and mice lacking TNFR1 develop mechanical 
hypersensitivity.  Although mechanisms responsible for local cytokine actions 
within muscle tissue in this model remain to be fully elucidated, in vitro studies 
demonstrate that an acidic environment inhibits the release of TNF from 
macrophages in response to lipopolysaccharide stimulation(297).  Intramuscular 
pH in the musculoskeletal sensitization model reaches roughly pH 6.5 post-
injection with acidified saline(114). Thus, the acidic microenvironment in the 
gastrocnemius muscle after acidified saline injection may inhibit TNF release.  
Collectively, observations that IL-1 and IL-6, but not TNF, contribute to the 
development of mechanical hypersensitivity following musculoskeletal 
sensitization represent novel findings of this study. 
Tissue acidosis, or an excess of hydrogen ions (H+), can be caused by 
many factors, including but not limited to insufficient cardiac function and sickle 
cell crises, tissue inflammation, and tumor microenvironments(298).  Each of 
these conditions produce acidosis that can cause pain(298).  Two primary 
pathways activate inflammation in muscle tissue; one characteristic of 
infection(299, 300) and the other from muscle fatigue(283, 301).  Infection in 
muscle tissue releases IL-1, IL-6, and TNF and activates the classical 
inflammatory pathways mediated by NF-κB(300, 302).  Fatiguing exercise 
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triggers predominantly IL-6 release(97, 303).  In human subjects, infusion of low 
pH buffer evokes symptoms characteristic of fatiguing muscle pain, including 
mechanical hyperalgesia and referred pain(276, 279, 304).  Although previous 
studies investigated the role of inflammatory cytokines in maintaining mechanical 
hypersensitivity after musculoskeletal sensitization in spinal cord, they did not 
quantify cytokine secretion in spinal cord or muscle tissue(305).  The effect of 
acidified saline injection into muscle has not been thoroughly investigated, but we 
detect IL-1 and IL-6, not TNF, in muscle tissue after injection.  These data 
suggest that injection of acidified saline triggers inflammatory pathways 
independent of TNF and may model fatiguing exercise more so than classical 
inflammatory pathways associated with infection. Although this is one possible 
explanation for cytokine release in muscle tissue, it warrants further study to 
elucidate the specific mechanism of action. 
Detection of H+ occurs through two receptors types; transient receptor 
potential cation channel subfamily V member 1(306) and the acid sensing ion 
channels (ASIC).  There are numerous ASIC channels, but ASIC3 is of particular 
interest because it is expressed exclusively on sensory neurons(307, 308).  
Inflammation increases the expression of ASIC3 on sensory neurons and 
therapeutic doses of non-steroidal anti-inflammatory drugs that reduce pain also 
prevent transcriptional increases of ASIC3(309).  Previous data suggest that 
ASIC3 plays a role in the development, but not maintenance, of musculoskeletal 
sensitization(118, 310, 311).  Pretreatment with a pharmacological antagonist for 
ASIC3, or genetic knockout of ASIC3, prevents mechanical hypersensitivity after 
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musculoskeletal sensitization.  However, targeting ASIC3 after hypersensitivity 
has developed is ineffective in ameliorating mechanical hypersensitivity(118, 
310, 311).  IL-1 increases the expression of ASIC3 mRNA in dorsal root ganglion 
cell cultures(312).  Although cytokines increase ASIC3 expression, a reciprocal 
role for ASIC3 in regulating cytokine expression is less clear.  ASIC3 expression 
in bone marrow derived macrophages in vitro is required for the maturation of 
immune cells that can secrete cytokines(313).  These data suggest the possibility 
that ASIC3 and inflammatory cytokines may have modulatory interactions, which 
in turn contributes to mechanical hypersensitivity.  Although the specific 
mechanisms of interactions between ASIC3 and inflammatory cytokines are not 
well understood, ASIC3 could modulate the release of cytokines.  This 
hypothesis remains to be tested. 
Collectively, our new data demonstrate that inflammatory cytokines and 
the transcription factor NF-κB play a critical role in the development of 
mechanical hypersensitivity after musculoskeletal sensitization.  Intramuscular 
injection with acidified saline causes a rapid rise in intramuscular IL-1 and IL-6 
concentrations.  Pre-treatment with an intracellular NF-κB inhibitor, or the genetic 
loss of IL-1R1 or IL-6 prevents the development of mechanical hypersensitivity.  
However, injection of acidified saline does not increase intramuscular TNF, and 
genetic loss of TNFR1 does not inhibit the effects of musculoskeletal 
sensitization.  These data drive future research focused on inflammatory 
cytokines as mediators of musculoskeletal sensitization.  Such research may 
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contribute to new treatments and help to reduce the high costs associated with 



































































Figure 11. Musculoskeletal sensitization injections increase intramuscular 
IL-1 and IL-6 
Data are plotted as the average cytokine concentration in pg/mL and presented 
only from the ipsilateral leg of mice injected with acidified saline.  For statistical 
comparisons, the pre-injection time-point was set to an arbitrary low value of 0.5 
pg/mL.  (A) IL-1 is significantly increased in mice injected with acidified saline at 
all time-points after injection 1 and 2.  (B) IL-6 is significantly increased across all 
three time-points after injection 1 but did not cross the threshold for detection 
after injection 2. n.d., cytokine concentration was not detectable and did not 
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Figure 12. Intramuscular inhibition of NF-κB blocks mechanical 
hypersensitivity following musculoskeletal sensitization 
The ipsilateral and contralateral leg for all injection groups did not significantly 
differ and data are presented only from the leg ipsilateral to injection (n=10 per 
treatment group).  At pre-injection baseline the mice subsequently randomized 
into injection groups did not significantly differ. Injection with the control peptide + 
acidified saline did result in a significant increase in mechanical hypersensitivity.  
Inhibitor peptide + acidified saline injection did not develop mechanical 
hypersensitivity that differed from either normal saline injection group (Inhibitor or 
control peptide).  Responsiveness to von Frey filaments are plotted as mean ± 
SEM of total response incidence percent ([total responses / total filament 
presentations] x 100) per paw.  *, p > 0.05 of Control peptide + acidified pH.  
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Figure 13. IL-1R1 and IL-6 knockout mice do not develop mechanical 
hypersensitivity following musculoskeletal sensitization 
Data are presented only from the leg ipsilateral to intramuscular injection (n=10 
per group).  For each panel knockout animals are plotted with the appropriate 
genetic control indicated in the figure legend.  (A) IL-1R1 and (B) IL-6 knockout 
mice fail to develop mechanical hypersensitivity after injection with acidified pH 
saline.  For both knockouts, the appropriate genetic controls develop mechanical 
hypersensitivity after injection with acidified saline.  (C) TNFR1 knockout mice 
develop mechanical hypersensitivity after injection with acidified that is not 
significantly different from WT mice injected with acidified saline.  
Responsiveness to von Frey filaments are plotted as mean ± SEM of total 
response incidence percent ([total responses / total filament presentations] x 
100) per paw.  +, p < 0.05 interaction effect between injection and genotype. *, p 





SUMMARY OF FINDINGS 
The data of this dissertation provide evidence for the interactions among 
musculoskeletal sensitization, disrupted sleep, and inflammatory cytokines.  
Briefly, the data presented in the previous chapters are reviewed. 
The quantification of sleep state in Chapter II demonstrates that for 3 weeks 
post-sensitization musculoskeletal sensitization increases the number of sleep 
state transitions during the light period without altering sleep duration.  In Chapter 
III data demonstrate that fragmenting the sleep of mice for 5 days between the 
first and second intramuscular injections alters behavioral outcomes after 
musculoskeletal sensitization.  Sleep fragmentation combined with 
musculoskeletal sensitization significantly increases state transitions of 
subsequent sleep during the light and dark periods for 3 weeks.  The increase in 
state transitions is accompanied by changes in the duration of NREM sleep, 
duration of wakefulness, and delta power during NREM sleep.  Sensitized mice 
that underwent SF are also hypersensitive to mechanical stimuli on day 1 and 
day 21 compared to sensitized mice with undisturbed sleep.  Chapter IV 
demonstrates a role for intramuscular inflammatory cytokines in musculoskeletal 
sensitization.  The inflammatory cytokines IL-1 and IL-6 significantly increase in 
muscle tissue injected with acidified, but not normal saline.  Pharmacological 
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manipulation to block nuclear translocation of NF-κB prevents mechanical 
hypersensitivity following musculoskeletal sensitization.   Lastly, genetic knockout 
of either IL-1R1 or IL-6, but not TNFR1, inhibits the development of mechanical 
hypersensitivity following musculoskeletal sensitization. Collectively, the data of 
this dissertation demonstrate that musculoskeletal sensitization increases the 
number of state transitions in the 3-weeks post-sensitization, intramuscular 
inflammatory cytokines play a mechanistic role in the development of mechanical 
hypersensitivity following musculoskeletal sensitization, and SF combined with 
musculoskeletal sensitization exacerbates the behavioral outcomes of sensitized 
mice including mechanical hypersensitivity and subsequent sleep. 
LIMITATIONS AND FUTURE DIRECTIONS 
The studies of this dissertation provide compelling data for the interactions of 
musculoskeletal sensitization and sleep; however, they are not without 
limitations.  The objectives of this dissertation were to determine whether 
musculoskeletal sensitization or SF combined with musculoskeletal sensitization 
has an impact on subsequent sleep.  Presumably, if alterations in sleep/wake 
behavior occur after musculoskeletal sensitization they would occur during the 
first 3 weeks post-sensitization.  Previous studies using musculoskeletal 
sensitization demonstrate it takes between 6 and 12 weeks for mechanical 
hypersensitivity to terminate(114).  The studies in this dissertation investigating 
sleep and mechanical hypersensitivity do not extend to include the resolution of 
mechanical hypersensitivity.  Therefore conclusions cannot be drawn about the 
whether sleep disruption occurs in parallel or independently of mechanical 
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hypersensitivity.  Future studies should investigate the full time course of effects 
for mechanical sensitization and sleep fragmentation. 
Chapter IV also has technical considerations surrounding the use of 
genetically manipulated mice.  IL-1R1 and TNFR1 knockout mice are receptor 
knockouts, while IL-6 is a ligand knockout.  This difference in genetic 
manipulation is considered in the experimental design and additional 
pharmacological and protein assay data were collected.  The results from the 
cytokine quantification assays and the genetic manipulations are consistent, and 
demonstrate that the IL-1 and IL-6, but not TNF systems playing a critical role in 
mechanical hypersensitivity. Another approach to investigate the role of 
cytokines in mechanical hypersensitivity would be the use of intramuscular 
pharmacological antagonists specific to IL-1, IL-6 and TNF.  This would confine 
the area of manipulation to the injection leg rather than the whole animal 
approach using genetically manipulated mice.  It would also enhance the 
cytokine specificity intramuscularly that the NF-кB inhibitor study did not provide.  
The technical considerations present opportunities for further research 
elucidating the specific mechanisms contributing to musculoskeletal sensitization 
and inflammatory cytokines. 
One topic not addressed in the data of this dissertation is potential sex 
differences in response to musculoskeletal sensitization, as only male mice were 
used.  Musculoskeletal pain in the human population is reported at roughly equal 
incidence rates in males and females(314), although females may be more 
sensitive to pressure pain associated with musculoskeletal discomfort(315).  In 
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preclinical studies of chronic pain and sleep, differential responses are detected 
between male and female rodents.  For example, preclinical studies of 
osteoarthritis in male and female rats detect that males have more disturbed 
sleep than females following osteoarthritis(198, 199).  However, sex differences 
in pain and sleep varies widely depending on the pain model of investigation.  An 
experimental model of temperomandibular joint inflammation detected pain and 
sleep disturbances in male rats, but no changes in female rats(316).  
Musculoskeletal sensitization has been induced in female CF-1 mice, however 
male mice were not investigated in the study and no sex differences in 
mechanical hypersensitivity can be inferred from the data(115).  The 
responsiveness of males and females to painful mechanical stimuli may be the 
result of sexual dimorphism in the threshold of mechanical nociceptors, which 
was recently demonstrated in vivo and in vitro in rats(317).  In female rats, the 
dorsal root ganglion cells that innervate the gastrocnemius muscle tissue have a 
significantly hyperpolarized resting potential compared with male rats(317).  This 
increase in the resting potential of nociceptors innervating muscle tissue 
corresponds with a significantly higher threshold for the firing of action potentials 
in females compared with males(317).  The sexual dimorphism of the response 
threshold of nociceptors innervating the gastrocnemius muscle tissue raises the 
possibility that musculoskeletal sensitization may have different effects in male 
and female rodents.  The data of this dissertation provide data that the 
musculoskeletal sensitization model in male mice causes interactions between 
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sleep and mechanical hypersensitivity, however this relationship still needs to be 
investigated with female mice. 
SLEEP AND PAIN INTEGRATION 
The data presented in the previous chapters demonstrate a role for 
intramuscular inflammatory cytokines in the development of mechanical 
hypersensitivity following musculoskeletal sensitization.  This is a novel finding, 
as mechanisms of musculoskeletal sensitization have not explored intramuscular 
actions but have focused on mechanisms in the spinal cord and brainstem(119, 
278, 305).  However, there are still questions surrounding the mechanisms 
maintaining the effects of musculoskeletal sensitization, particularly the 
interactions with sleep/wake behavior.  The biological mechanisms independently 
underlying sleep and chronic pain are complex(111, 318).  There are specific 
brain regions of intersection critical for the regulation of sleep and pain.  The 
brainstem is the site of several arousal-promoting nuclei that send projections to 
higher cortical areas and contribute to wakefulness(319, 320).  The brainstem 
also modulates pain by sending descending projections to the spinal cord and 
ascending projections to the amygdala and somatosensory cortices(113, 211, 
321, 322).  The rostral ventromedial medulla (RVM) regulates the peripheral 
sensory processing of painful stimuli(211).  Injections of opioids, anesthetics, and 
cholinergic antagonists into the RVM can block a variety of painful stimuli, 
including mechanical hypersensitivity(110, 119, 214, 216, 217, 323).  These data 
demonstrate the importance of the RVM in pain regulation during painful 
conditions including musculoskeletal pain. 
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The RVM regulates pain and sends projections to other nuclei associated with 
sleep.  Histological studies of direct projections from the RVM identify outputs to 
a number of nuclei including the periaqueductal gray (PAG)(107, 108).  The PAG 
is a nucleus of the midbrain that is adjacent to the cerebral aqueduct.  The 
proximity of the PAG to the cerebrospinal fluid suggests a potential role in 
integrating between the central and peripheral nervous system.  The PAG is one 
of the last nuclei in the descending pain pathway in the central nervous 
system(107, 108, 324).  It also serves a function in sleep regulation and lesions 
of the PAG cause loss of consciousness(212, 325).  In a rodent model of sciatic 
nerve injury, severity of pain and sleep disturbance is correlated with cell death in 
the PAG(166, 326).  Although the PAG is one of numerous nuclei associated with 
pain, it is one of the few contributing to both sleep and pain.  These data suggest 
that the PAG may warrant further investigation for its roles in sleep and pain 
during musculoskeletal sensitization. 
ACIDOSIS MECHANISMS 
The sensing of tissue pH both centrally and peripherally is critical to health.  
Changes in pH are associated with pathological conditions including ischemia, 
myopathies, and exhausting exercise(274).  Two receptors detect hydrogen ions 
(H+); TRPV1 and the ASIC family of receptors(327).  TRPV1 is well characterized 
for its role in sensing capsaicin, the active ingredient in chili peppers, and TRPV1 
has functions in thermoregulation and heat sensation(306).  Of the ASIC family of 
receptors, ASIC3 is of interest as its expression is limited to sensory neurons in 
the peripheral nervous system(328).  ASIC3 serves a critical role in the 
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development, but not the maintenance of mechanical hypersensitivity following 
musculoskeletal sensitization(118, 310, 311, 329).  Pharmacological targeting of 
ASIC3 is not a viable therapeutic treatment for mechanical hypersensitivity 
because ASIC3 does not maintain mechanical hypersensitivity but does 
contribute to mechanistic understanding. 
 The interactions between ASIC3 and inflammatory cytokines are largely 
unknown.  The data contained in Chapter IV demonstrate that inhibition of 
nuclear translocation of NF-κB prior to sensitization can block mechanical 
hypersensitivity, presumably by regulating the transcription of the inflammatory 
cytokines IL-1 and IL-6 that increase in muscle tissue after injection with acidified 
saline.  Genetic manipulation of the IL-1 and IL-6 systems also prevents 
mechanical hypersensitivity after musculoskeletal sensitization.  Prior studies 
demonstrate that pharmacological blockade of ASIC3 or genetic loss of the 
receptor prior to sensitization blocks mechanical hypersensitivity following 
musculoskeletal sensitization(310, 311, 329, 330). Although few studies have 
investigated the release of cytokines after activation of ASIC3 through acidosis, 
one in vitro study found increases in activated immune cells that release 
cytokines after acidosis in an ASIC3 dependent manner(313).  An in vivo 
experiment using ASIC3 knockout mice with experimental arthritis detected 
increases in inflammation, especially IL-6, that was paradoxically associated with 
a reduction of pain(331).  This limited data on the influence of ASIC3 activation 




Animal models in biomedical research provide invaluable information on basic 
biology and pioneering treatments for diseases.  Pre-clinical research is critical 
for performing studies that are too complex, costly, or dangerous to be performed 
with human subjects.  The foundation of biological knowledge is derived from the 
results of studies that are invasive, intrusive, and potentially terminal.  
Pharmacological, surgical, and electrophysiological studies cannot generally use 
human subjects because of the unknown and potentially irreversible outcomes.  
For these reasons model organisms, including non-human primates, cats, dogs, 
rats, mice, fish, birds, and flies are used.  Rodents, including rats and mice, are 
one of the most frequently used models in biomedical research.  The sequencing 
of the mouse genome and creation of transgenic and knockout mouse lines has 
transformed the field of biomedical research.  Yet the question still remains as to 
how translatable findings in rodents are for the reduction of disease burden in 
humans and contribution to public health.  The role of rodent models within the 
fields of pain and sleep research are briefly discussed. 
PAIN MODELS 
Experimental pain models are cost-effective tools for the development and 
screening of analgesic treatments, however their translational value to humans is 
under scrutiny(159).  Analgesics are the most prescribed pharmacological agents 
in the United States(332). Recently, several treatments developed using pre-
clinical research techniques failed to translate successfully to human analgesia 
including the neurokinin 1 (substance P) receptor antagonists(333), sodium 
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channel blockers(334), and glycine-site antagonists(335).  All of these 
interventions treated pain in pre-clinical trials only to fail early in human trials.  
These examples illustrate that despite drug safety and efficacy in animal models, 
there may be adverse side effects or a lack of analgesic benefit in humans(336).  
The absence of translational value from animal models in pain research has led 
to the suggestion that human subjects be utilized in the early stages of pain 
research(337).  Although the use of human subjects is not without it’s own ethical 
dilemmas, it may improve the success rate of treatment development.  The 
breakdown between pre-clinical research and human testing poses a significant 
challenge to the treatment of pain and new opportunities need to be explored to 
develop successful treatments.   
The challenges of animal research extend beyond the field of pain to 
immunology research(336).  Recently, the translational value of sepsis research 
in rodent models is being called into question(338).  The inflammatory pathways 
critical to the regulation and escalation of the inflammatory process during 
sepsis, a severe infection of the blood, are not the same in mice and 
humans(339). While this paper provides compelling data, it is also limited by only 
using one inbred mouse strain and does not reflect the genetic diversity of 
human sampling(338).  These data challenge the field to examine the possibility 
of using alternate model systems, including pigs, which have an immune system 
more similar to humans(340).  A global challenge like sepsis that requires an 
ongoing immune response may require an animal that more closely models 
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human physiology.  The field of immunology provides one example of a 
breakdown between rodent research and the human condition.  
The study of pain by its very nature requires the induction of physical 
discomfort that is not diminished through the use of analgesics.  While this is not 
an insignificant undertaking ethically, the results are critical to understand 
biological mechanisms of pain.  Pre-clinical models of pain focus on surgical 
manipulation, peripheral or systemic administration of exogenous agents, and 
pain as the result of disease states including cancer and diabetes(158).  
Research models cover a range of pain types including neuropathic, arthritic, 
immune, and cancer pain(158, 159).  Substantial research is devoted to the 
study of neuropathic pain using surgical manipulation of the sciatic nerve(113, 
321).  Despite the contributions of these studies, neuropathic pain does not have 
the highest prevalence rates in the human population(4).  Musculoskeletal pain 
contributes to three of the most prevalent pain conditions in the United States, 
represents one of the biggest barriers in returning to work after a workplace 
accident, and has some of the poorest patient reported rates of control(4, 100, 
341).  Investigations of the mechanisms of pain should consider epidemiological 
data and direct resources towards pain conditions prominent in public health.  
The implementation of better pre-clinical models of musculoskeletal pain, as well 
as more clinical research, may increase mechanistic understanding and novel 
translational approaches for musculoskeletal pain.  Increasing mechanistic 
understanding and improving treatments of conditions involving musculoskeletal 
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pain will ultimately reduce the public health burden and improve patient quality of 
life.   
The quantification of acute and ongoing pain in pre-clinical pain research is 
one of the significant challenges in the field. Research utilizes evoked and 
spontaneous behavioral tests prior to and following experimental manipulations 
to detect changes in pain(342).  Pain can also be quantified between pre- and 
post-manipulation values, as well as placebo and experimental groups.  
However, the complex and diverse qualities of pain are not captured by these 
methods.  The lexicon of terms describing pain in humans is rich with descriptors 
including burning, searing, tearing, throbbing, dull, aching, sharp, radiating, 
pressure, piercing, and tingling.  Examining an animal that is hunched, 
demonstrating a weight bearing preference, or limping does not capture the 
qualitative nature of the pain. Similarly, tests of chemical, cold, heat, and 
pressure pain give a snapshot of an increase in responsiveness, reduction in 
threshold, or exacerbation of behavioral response, but not the burden of pain.  
This is difficult to extrapolate to chronic pain patients who execute day-to-day 
functioning in the face of tremendous discomfort.  The development and 
validation of new techniques to measure pain in rodents is an area of progress 
for pre-clinical research.  Unfortunately techniques requiring pre-training of 
animals to behaviorally respond and distinguish intensities of pain significantly 
slow the throughput on experiments and increase the costs of experiments(343, 
344).  The pre-clinical classification of pain is a critical factor in the translation of 




The duration and distribution of sleep across the day of humans is 
different from that of rodents.  Human sleep is consolidated to one sleep bout of 
approximately 8-hours during the dark period.  In contrast, rodents are nocturnal 
polyphasic sleepers with shorter sleep bouts across the day with the largest 
consolidated sleep bouts occurring during the light period(345). One important 
difference between human and rodent sleep is the amount of time spent in REM 
sleep.  Humans spend roughly 25% of the sleep period in REM sleep while 
rodents average between 7-10%(345).  Despite the differences between human 
and rodent sleep there are many similarities, including the preservation of 
spectral characteristics of the EEG.  Spectral similarities include the increase in 
high-amplitude EEG slow-wave activity during NREM sleep(345).  Sleep 
responses to pathological conditions are also similar between the species.  
During acute infection humans and rodents increase NREM sleep that coincides 
with fever(346). Despite the differences between human and rodent sleep, 
laboratory mice and rats continue to be useful models for the study of sleep 
physiology. 
Sleep deficits are a risk factor for pain, raising the question of whether 
enhancement of sleep can improve pain? Studies investigating the use of 
Zolpidem, a sleep aid, during the post-surgical recovery period of patients 
undergoing reconstructive knee surgery find that Zolpidem improves post-
surgical pain(251, 252). Patients given Zolpidem as part of the medication regime 
during recovery report less subjective pain during the entire recovery period and 
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also require fewer analgesics to control their pain(251, 252).  This finding is 
significant because opioids that are used to treat pain after surgical procedures 
are highly addictive, and can rapidly lose efficacy if taken in high doses(347).  
Opioids also contribute to the fragmentation of sleep, especially when taken for 
prolonged periods(257, 258).  While data demonstrate the efficacy of Zolpidem in 
reducing pain burden after surgery, this should not bolster the market for 
somnogenic agents as a post-surgical medication.  Non-pharmacological 
treatments have also been successfully used to treat sleep disorders and 
improve chronic pain. Cognitive behavioral therapy in patients with chronic pain, 
including musculoskeletal pain, improves subjective sleep quality and reduces 
pain(230, 231, 348). The use of pharmacological and behavioral treatments may 
contribute to a reduction in subjective pain, improvement in sleep quality, and 
decreased need for analgesic treatment in patients with chronic pain or 
undergoing painful procedures.   
Adults, children, and adolescents all have declining sleep durations in the 
United States(3, 349).  Cognitive behavioral therapy is one of the most 
successful treatments of insomnia(350), and is effective in improving sleep and 
pain symptoms in patients with chronic pain(351).  Sleep is not a subject that is 
universally addressed in public education health classes, nor at higher levels of 
education(352).  Given the pervasive nature of disordered sleep in the United 
States, education about establishing healthy sleep habits may curtail national 
sleep trends and improve the health of future generations(349, 353). Sleep is 
often overlooked until a precipitating event or injury, such as falling asleep while 
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driving.  Although a simple technique, sleep education may reduce the number of 
persons voluntarily curtailing their sleep.  
CONCLUDING REMARKS 
Collectively, data presented in this dissertation contribute to our 
knowledge of the mechanistic interactions of musculoskeletal pain on sleep, the 
role of inflammatory cytokines on mechanical hypersensitivity, and demonstrate 
that SF combined with musculoskeletal sensitization exacerbates behavioral 
outcomes. The data indicate that musculoskeletal sensitization is a model useful 
in studying CNS interactions between pain and sleep. The burden of 
musculoskeletal pain in the general population encourages research into 
biological mechanisms of muscle pain and interactions with sleep.  The physical, 
psychological, and emotional burden of pain, especially in conjunction with sleep 
disruption, tremendously impairs the daily functioning of patients. Research of 
the intersections between sleep and pain is necessary to develop effective 
treatments and reduce patient suffering associated with ongoing chronic pain and 
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